{"gene":"APOA1","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1972,"finding":"APOA1 acts as a protein cofactor (activator) of lecithin:cholesterol acyltransferase (LCAT), stimulating the esterification of cholesterol in plasma.","method":"In vitro biochemical reconstitution assay measuring LCAT activity in the presence and absence of apolipoprotein fractions","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — original reconstitution assay, foundational finding with 694 citations and independently replicated across decades","pmids":["4335615"],"is_preprint":false},{"year":1973,"finding":"APOA1-containing high-density lipoproteins donate apolipoprotein C activators (lipoprotein lipase activators) to chylomicrons during alimentary lipemia, demonstrating that APOA1/HDL particles serve as a reservoir for exchangeable apolipoproteins that transfer between lipoprotein classes during triglyceride metabolism.","method":"In vivo metabolic study in humans measuring apolipoprotein distribution across lipoprotein fractions before and after fat meals; polyacrylamide gel electrophoresis and biochemical quantification","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — in vivo quantitative measurement with 514 citations; directly demonstrates apolipoprotein exchange between lipoprotein classes","pmids":["4345202"],"is_preprint":false},{"year":2004,"finding":"APOA1 is a selective target for myeloperoxidase (MPO)-catalyzed nitration and chlorination in vivo; MPO binds directly to APOA1 on HDL particles, and MPO-mediated oxidative modification of APOA1 selectively inhibits ABCA1-dependent cholesterol efflux from macrophages, converting HDL into a dysfunctional, proatherogenic form.","method":"Cross-immunoprecipitation of MPO with apoA-I in plasma; mass spectrometry quantification of nitrotyrosine and chlorotyrosine in apoA-I from serum and atherosclerotic lesions; ABCA1-dependent [³H]-cholesterol efflux assays from macrophages; identification of MPO-apoA-I contact site","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (co-IP, MS, functional efflux assay, lesion analysis), 575 citations, strong mechanistic evidence","pmids":["15314690"],"is_preprint":false},{"year":2004,"finding":"Rare nonsynonymous variants in APOA1 (along with ABCA1 and LCAT) are significantly more common in individuals with low HDL-C (<5th percentile) than high HDL-C (>95th percentile), and most such variants are functionally important as demonstrated by biochemical studies, establishing that rare loss-of-function alleles in APOA1 collectively contribute substantially to low plasma HDL levels in the general population.","method":"Population-based resequencing of APOA1, ABCA1, and LCAT; biochemical functional studies of identified variants","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — resequencing combined with functional biochemical validation; 829 citations; replicated in independent population","pmids":["15297675"],"is_preprint":false},{"year":2009,"finding":"Amyloidogenic APOA1 mutations cluster in two hot-spot regions (residues 50–93 and 170–178) of the mature protein; mutations in residues 1–75 predominantly cause hepatic and renal amyloidosis, while mutations in residues 173–178 cause cardiac, laryngeal, and cutaneous amyloidosis, establishing a genotype–phenotype correlation linking mutation position to organ tropism of AApoAI amyloid deposition.","method":"Sequencing of APOA1 germline mutations in patients with biopsy-confirmed amyloidosis; Congo red staining with polarized light; immunohistochemistry with anti-apoAI antibodies; identification of three novel frameshift and missense mutations","journal":"The Journal of molecular diagnostics","confidence":"High","confidence_rationale":"Tier 2 — direct sequencing with pathological confirmation across multiple patients; supported by prior literature on 16 total mutations establishing hot-spot pattern","pmids":["19324996"],"is_preprint":false},{"year":2011,"finding":"On spherical HDL (sHDL), three APOA1 chains adopt a helical dimer with hairpin (HdHp) architecture as the most consistent global structure, forming a hollow protein shell that cradles a central compact lipid core, as determined by small-angle neutron scattering with contrast variation combined with chemical cross-linking and mass spectrometry.","method":"Small-angle neutron scattering (SANS) with contrast variation on reconstituted sHDL; chemical cross-linking followed by mass spectrometry to discriminate among three structural models (HdHp, 3Hp, iT)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — solution structural method with orthogonal cross-linking/MS validation; replicated aspects consistent with prior structural studies","pmids":["21292766"],"is_preprint":false},{"year":2011,"finding":"APOA1 synthesized by small intestinal enterocytes is secreted apically and deposits in the brush border membrane, where it associates with cholesterol in detergent-resistant lipid raft microdomains; bile salts (taurocholate) efficiently release brush-border APOA1 at sub-solubilizing concentrations, and this apically localized APOA1 is proposed to mediate transintestinal cholesterol efflux (TICE) into the gut lumen.","method":"Immunomicroscopy and subcellular fractionation of porcine small intestine; immunoisolation of microvillar vesicles; cholesterol detection in apoA-1 immunoisolates; detergent-resistant membrane (DRM) fractionation; treatment with phospholipase C, trypsin, bile salts; comparison with aminopeptidase N as transmembrane control","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization with functional fractionation and release experiments; single lab, but multiple orthogonal methods","pmids":["22119776"],"is_preprint":false},{"year":2013,"finding":"In vivo tissue cholesterol efflux (TCE) is reduced by 19% in carriers of the L202P mutation in APOA1 compared to controls with normal HDL-C, demonstrating that functional APOA1 directly mediates cholesterol efflux from peripheral tissues in humans; residual TCE and unaffected fecal sterol excretion indicate that non-HDL pathways also substantially contribute to reverse cholesterol transport.","method":"In vivo stable isotope infusion of ¹³C₂-cholesterol in APOA1 L202P mutation carriers and controls; three-compartment SAAM-II kinetic modeling of plasma and erythrocyte cholesterol enrichment; fecal ¹³C recovery measurement","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo stable isotope kinetic study with defined genetic model and quantitative readout; directly establishes APOA1 role in tissue cholesterol efflux in humans","pmids":["23650622"],"is_preprint":false},{"year":2015,"finding":"The N-terminal domain of full-length APOA1 participates as an integrated part of the protein belt (not as a separate globular domain) stabilizing discoidal APOA1-POPC-cholesterol particles; upon cholesterol incorporation, the N-terminal domain allows bilayer thickness to increase while maintaining a flat bilayer structure, in contrast to the N-terminal-truncated nanodisc system which adopts an energetically strained lens shape.","method":"Small-angle X-ray scattering (SAXS) with molecular constrained data modeling of reconstituted APOA1-POPC-cholesterol discoidal particles; comparison with N-terminal truncated nanodisc system across increasing cholesterol concentrations","journal":"Biophysical journal","confidence":"Medium","confidence_rationale":"Tier 1 — structural method (SAXS) with modeling; single lab and no mutagenesis validation, but clear structural conclusions","pmids":["26200866"],"is_preprint":false},{"year":2018,"finding":"APOA1 uses a reciprocating thumbwheel-like mechanism to activate LCAT on nascent discoidal HDL: most APOA1 adopts a 5/5 helical registry (helix 5 of one molecule across from helix 5 of the other), but a fraction adopts a 5/2 registry; the 5/2 registry, locked by engineered disulfide bonds, impairs LCAT cholesteryl esterification activity without affecting LCAT binding or macrophage cholesterol efflux, indicating that full LCAT activation requires a hybrid epitope composed of helices 5–7 on one APOA1 molecule and helices 3–4 on the other.","method":"Site-directed mutagenesis introducing cysteines at predicted interface positions; disulfide bond locking of specific helical registries; LCAT cholesteryl esterification assay; macrophage cholesterol efflux assay; chemical cross-linking studies","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis combined with functional reconstitution assays and cross-linking structural data; direct mechanistic demonstration of registry-dependent LCAT activation","pmids":["29773713"],"is_preprint":false},{"year":2016,"finding":"ApoA1 interacts directly with dengue virus (DENV) non-structural protein 1 (NS1); ApoA1-mediated depletion of lipid rafts from cell membranes inhibits DENV attachment to the cell surface, and ApoA1 neutralizes NS1-induced cell activation and NS1-mediated enhancement of DENV infection, identifying a mechanism by which ApoA1/HDL-mediated reverse cholesterol transport controls viral infection.","method":"Co-immunoprecipitation and binding assays between DENV NS1 and ApoA1; lipid raft quantification in cell membranes; DENV infectivity assays with ApoA1 and ApoA1 mimetic peptide 4F; cell activation assays","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct binding demonstrated with functional infectivity and cell activation assays; single lab but multiple orthogonal readouts","pmids":["33827950"],"is_preprint":false},{"year":2016,"finding":"ApoA1 (and ApoJ/Clusterin) modulate amyloid-β1-40 transport across the blood-brain barrier (BBB) by distinct mechanisms: ApoA1 complexed with Aβ1-40 does not enhance Aβ efflux from the brain, but ApoA1 present in the apical (blood) compartment mobilizes Aβ1-40 from the basolateral (brain) side; both ApoA1 and ApoJ cross the BBB via a mechanism involving the LDL receptor-related protein family, but ApoA1 trafficking is restricted when bound to Aβ.","method":"In vitro BBB model using primary cerebral endothelial cells on Matrigel-coated Transwells; fluorescently labeled Aβ1-40 transport assays; LRP family inhibitor experiments; measurement of bidirectional transport of recombinant ApoA1 and ApoJ","journal":"Journal of Alzheimer's disease","confidence":"Medium","confidence_rationale":"Tier 2 — reconstituted in vitro BBB model with pharmacological pathway dissection; single lab","pmids":["27232214"],"is_preprint":false},{"year":2016,"finding":"ApoA1 binds heparin simultaneously with serum amyloid A (SAA) on HDL isolated from inflamed mice, forming rapid complex aggregates; mass spectrometry of chemically cross-linked HDL-SAA particles detected multiple cross-links between ApoA1 and SAA, indicating these two proteins are in close proximity (within 25 Å) on the HDL surface, providing a structural basis for simultaneous heparin binding.","method":"Gel electrophoresis of heparin-HDL complexes; mass spectrometry analysis of chemically cross-linked apoA1-SAA peptides from inflammation-associated HDL","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — chemical cross-linking with MS identifies proximity of ApoA1 and SAA on HDL surface; single lab","pmids":["27105909"],"is_preprint":false},{"year":2020,"finding":"ApoA-1 improves glucose tolerance in high-fat diet-fed mice by increasing glucose uptake into skeletal muscle (+110%) and heart (+100%) independently of AMPKα2 kinase activity; the insulin-independent component of this effect requires systemic factors not present in isolated muscle ex vivo, suggesting ApoA-1 acts through an indirect systemic mechanism rather than direct muscle cell signaling via AMPKα2.","method":"Recombinant human ApoA-1 injection in wild-type and AMPKα2 kinase-dead mice; glucose tolerance tests with/without insulin secretion block (epinephrine + propranolol); radiolabeled glucose uptake into isolated tissues; isolated skeletal muscle ex vivo glucose uptake assay","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo genetic epistasis (kinase-dead mice) combined with pharmacological block and ex vivo muscle assay; multiple orthogonal readouts ruling out AMPKα2 dependence","pmids":["32244181"],"is_preprint":false},{"year":2020,"finding":"HDL and ApoA-1 suppress glucagon expression and secretion from pancreatic α-cells via binding to SCARB-1 (scavenger receptor class B type 1) and activating the PI3K/Akt/FoxO1 signaling cascade; pretreatment with Akt inhibitor VIII, PI3K inhibitor LY294002, or SCARB-1 inhibitor BLT-1 restores α-cell response to low glucose, establishing the receptor and downstream pathway.","method":"Treatment of αTC1 clone 6 cells with HDL or ApoA-1; glucagon expression (RT-PCR) and secretion assays; western blotting for Akt and FoxO1 phosphorylation; pharmacological inhibitors of Akt, PI3K, and SCARB-1; in vivo HDL/ApoA-1 injection in CD1 mice measuring glucagon response to insulin-induced hypoglycemia","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro pathway dissection with multiple inhibitors plus in vivo validation; single lab","pmids":["33086869"],"is_preprint":false},{"year":2021,"finding":"TRIM15 interacts with APOA1 through its PRY/SPRY domain and promotes APOA1 polyubiquitination via its RING domain, leading to APOA1 proteasomal degradation; loss of APOA1 enhances lipid anabolism, promotes lipid droplet accumulation, and drives pancreatic cancer cell invasion and metastasis via the APOA1-LDLR axis regulating triglyceride synthesis.","method":"Mass spectrometry identification of TRIM15 binding partners; co-immunoprecipitation of TRIM15 and APOA1; domain-mapping experiments with PRY/SPRY and RING domain mutants; ubiquitination assay; lipid droplet staining; TRIM15 silencing with invasion/migration assays; LDLR pathway analysis","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 — MS-identified interaction confirmed by co-IP with domain mapping and functional ubiquitination assay; single lab","pmids":["34311082"],"is_preprint":false},{"year":2021,"finding":"Targeting the Apoa1 locus in mouse liver with CRISPR-Cas9/AAV delivery achieves 6–16% targeted hepatocyte editing; the endogenous Apoa1 promoter drives robust and sustained hepatic expression of therapeutic transgenes (APOE, FAH), validating Apoa1 as a functional integration site for liver-directed gene therapy.","method":"AAV delivery of CRISPR-Cas9 targeting mouse Apoa1 locus; quantification of targeted integration rates; plasma lipid measurement in hypercholesterolemia model after APOE knock-in; phenotypic rescue of hereditary tyrosinemia type I by FAH knock-in","journal":"Molecular therapy. Methods & clinical development","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genome editing with functional rescue phenotype; demonstrates promoter activity for transgene expression; single lab","pmids":["34141821"],"is_preprint":false},{"year":2023,"finding":"In small HDL particles, the C-termini of the two antiparallel APOA1 molecules are 'flipped' off the lipid surface, adopting an extended conformation that engages ABCA1 to promote cholesterol efflux; in larger HDL particles, the C-termini form a helical bundle that adheres strongly to the lipid surface, preventing productive ABCA1 interaction. LCAT activity converts small/extra-small HDL into larger particles and markedly inhibits cholesterol efflux capacity, confirming this structural mechanism.","method":"Tandem mass spectrometric analysis of chemically cross-linked peptides from reconstituted HDL of four sizes; molecular dynamics simulations of APOA1 conformations; macrophage ABCA1-dependent cholesterol efflux capacity assays; isolation of HDL from LCAT-deficient subjects; incubation with human LCAT to convert particle size distributions","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1 — structural (cross-linking MS + MD simulation) combined with functional efflux assay and human genetic model (LCAT deficiency); multiple orthogonal methods supporting same mechanism","pmids":["38018436"],"is_preprint":false},{"year":2024,"finding":"In human scleral fibroblasts under hypoxia, FOXM1 represses METTL3 transcription (demonstrated by ChIP showing FOXM1 enrichment at the METTL3 promoter); reduced METTL3 decreases m6A methylation of APOA1 mRNA, reducing YTHDF2-mediated mRNA degradation and thereby stabilizing/increasing APOA1 expression; elevated APOA1 promotes myofibroblast transdifferentiation (elevated vinculin, paxillin, α-SMA) and inhibits collagen production, contributing to scleral remodeling in myopia.","method":"ChIP assay for FOXM1 at METTL3 promoter; Me-RIP to measure m6A modification of APOA1 mRNA; PAR-CLIP to examine METTL3-APOA1 mRNA binding; loss/gain-of-function experiments (siRNA knockdown, overexpression); western blotting and RT-qPCR for myofibroblast markers; CCK-8 proliferation and flow cytometry apoptosis assays","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and Me-RIP establish mechanistic pathway; PAR-CLIP confirms binding; multiple functional readouts; single lab","pmids":["38190128"],"is_preprint":false},{"year":2013,"finding":"ABCA1-dependent vitamin E (tocopherol) secretion from Caco-2 intestinal cells to APOA1 (but not HDL) is vitamer-selective: T0901317-induced ABCA1 expression drives α- and γ-tocopherol secretion to apical APOA1 more efficiently than δ-tocopherol, while APOB-dependent secretion (accounting for ~80% of total) shows no such selectivity, establishing APOA1 as the acceptor that confers selective tocopherol secretion via the ABCA1 pathway.","method":"Caco-2 polarized monolayer system with apical co-incubation of three tocopherols; MTP inhibitor (BMS201038) to quantify apoB-dependent pathway; LXR agonist T0901317 to induce ABCA1; basolateral APOA1 acceptor assays; SR-BI blocking antibody; quantification of tocopherol and cholesterol secretion","journal":"The Journal of nutrition","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological pathway dissection in polarized cells with multiple inhibitors; directly demonstrates APOA1 as selective acceptor for ABCA1-mediated tocopherol secretion; single lab","pmids":["23946344"],"is_preprint":false},{"year":1989,"finding":"APOA1 binds to triglyceride-rich emulsion particles (model of triglyceride-rich lipoproteins) in a saturable manner with dissociation constant Kd = 7.4 × 10⁻⁷ M; when particle cholesterol content is elevated above the physiological range (>3.7% to 7.3%), the protein binding capacity (N) sharply decreases ~6-fold without changing Kd, suggesting that excess cholesterol content impairs apolipoprotein redistribution and remnant metabolism.","method":"Binding of APOA1 and ApoE-3 to isolated triglyceride-phospholipid emulsions of varying cholesterol content; negative stain EM; Scatchard analysis of saturable binding","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro reconstitution binding assay with quantitative kinetics; establishes cholesterol-dependent regulation of APOA1 binding capacity","pmids":["2496752"],"is_preprint":false},{"year":2016,"finding":"Following neuronal injury, APOA1 expression increases in a delayed secondary phase response; exogenous ApoA1 treatment accelerates wound closure in a neuroblastoma scratch assay via activation of the ERK signaling pathway and actin polymerization, suggesting ApoA1 plays a functional role in post-injury neuronal healing through these downstream effectors.","method":"Proteomics of spinal cord injury tissue at multiple time points; scratch wound healing assay in neuroblastoma cells with ApoA1 treatment; western blotting for ERK pathway activation; actin polymerization assay","journal":"Molecular and cellular biochemistry","confidence":"Low","confidence_rationale":"Tier 3 — single lab, limited mechanistic depth; ERK activation and actin polymerization shown but pathway not rigorously dissected","pmids":["27734225"],"is_preprint":false},{"year":2012,"finding":"ApoA1 mimetic peptide L-4F increases insulin-receptor phosphorylation in mesenchymal stem cell-derived adipocytes via upregulation of heme oxygenase-1 (HO-1); HO activity inhibition reverses L-4F-induced effects on adipogenic markers (increases in WNT10b, decreases in Peg1/Mest), establishing that L-4F acts through an HO-1-dependent mechanism to restore adiponectin secretion, decrease inflammatory cytokines, and improve insulin sensitivity in obese mice.","method":"In vivo L-4F administration to ob/ob mice; western blotting for HO-1, insulin receptor phosphorylation, WNT10b, Peg1/Mest; HO activity inhibition pharmacological experiments; adiponectin and cytokine ELISA; cell cycle analysis of MSC-derived adipocytes","journal":"Cell cycle","confidence":"Low","confidence_rationale":"Tier 3 — mimetic peptide (not canonical APOA1 protein), pathway partially mapped; single lab","pmids":["22306989"],"is_preprint":false}],"current_model":"APOA1, the principal protein of HDL, mediates reverse cholesterol transport by acting as the obligate cofactor of LCAT (activating cholesterol esterification through a thumbwheel-like helical registry mechanism), accepting cholesterol from peripheral cells via ABCA1-dependent efflux (with the C-termini of APOA1 on small HDL particles adopting a flipped conformation that engages ABCA1), and exchanging between lipoprotein classes; its activity is impaired by myeloperoxidase-catalyzed oxidation/nitration at specific residues, regulated post-translationally by TRIM15-mediated ubiquitination and degradation, and modulatable through m6A methylation of its mRNA via the FOXM1/METTL3/YTHDF2 axis; APOA1 additionally activates PI3K/Akt/FoxO1 signaling in pancreatic α-cells through SCARB-1 to suppress glucagon secretion, modulates Aβ transport across the blood-brain barrier via LRP family receptors, and neutralizes dengue virus NS1-mediated lipid raft remodeling."},"narrative":{"teleology":[{"year":1972,"claim":"Establishing that APOA1 is the obligate protein cofactor for LCAT resolved how plasma cholesterol esterification is catalyzed and positioned APOA1 as the central functional component of HDL-mediated lipid metabolism.","evidence":"In vitro reconstitution assay measuring LCAT activity with and without apolipoprotein fractions","pmids":["4335615"],"confidence":"High","gaps":["Structural basis of LCAT activation by APOA1 was unknown","Which APOA1 domains are required for activation was not determined"]},{"year":1973,"claim":"Demonstrating that HDL/APOA1 particles donate exchangeable apolipoproteins (apoC) to chylomicrons during alimentary lipemia established HDL as a dynamic reservoir that facilitates triglyceride metabolism across lipoprotein classes.","evidence":"In vivo human metabolic study with apolipoprotein quantification across lipoprotein fractions before and after fat meals","pmids":["4345202"],"confidence":"High","gaps":["Mechanism of apolipoprotein transfer between particles was not defined","Role of specific APOA1 domains in exchange was unknown"]},{"year":1989,"claim":"Quantifying APOA1 binding to triglyceride-rich emulsion particles and showing that excess cholesterol sharply reduces binding capacity revealed a lipid-composition-dependent gating mechanism for apolipoprotein redistribution.","evidence":"In vitro binding assay with Scatchard analysis on TG-phospholipid emulsions of varying cholesterol content","pmids":["2496752"],"confidence":"Medium","gaps":["Whether this binding modulation occurs on native lipoproteins in vivo was not tested","Structural basis of cholesterol-induced reduction in binding sites was not resolved"]},{"year":2004,"claim":"Identifying myeloperoxidase as a direct binding partner that nitrates/chlorinates APOA1 on HDL and selectively impairs ABCA1-dependent cholesterol efflux established a molecular mechanism for generating dysfunctional HDL in atherosclerotic disease.","evidence":"Co-immunoprecipitation, mass spectrometry of oxidative modifications in lesion-derived APOA1, and macrophage cholesterol efflux assays","pmids":["15314690"],"confidence":"High","gaps":["Which specific modified residues are responsible for efflux impairment was not fully resolved","Whether MPO-modified APOA1 gains toxic gain-of-function activities was not addressed"]},{"year":2004,"claim":"Population-based resequencing with functional validation showed that rare loss-of-function APOA1 variants collectively explain a substantial fraction of low HDL-C in the general population, establishing APOA1 as a direct genetic determinant of plasma HDL levels.","evidence":"Resequencing of APOA1 in extreme HDL-C phenotype groups with biochemical functional studies of variants","pmids":["15297675"],"confidence":"High","gaps":["Effect sizes of individual rare variants on cardiovascular outcomes were not determined","Functional consequences beyond HDL-C levels (e.g., efflux capacity) were not measured for each variant"]},{"year":2009,"claim":"Mapping amyloidogenic APOA1 mutations to two hot-spot regions and correlating mutation position with organ-specific amyloid deposition established genotype–phenotype relationships for hereditary AApoAI amyloidosis.","evidence":"Germline sequencing and Congo red/immunohistochemistry-confirmed biopsy across multiple patients","pmids":["19324996"],"confidence":"High","gaps":["Structural basis for why different regions produce different amyloid fibrils with different tissue tropism was unknown","Whether amyloid toxicity is from loss of HDL function or gain-of-function aggregation was not resolved"]},{"year":2011,"claim":"Determining that three APOA1 chains form a helical dimer-with-hairpin architecture on spherical HDL provided the first solution-phase structural model of mature HDL, resolving how a protein shell cradles a lipid core.","evidence":"Small-angle neutron scattering with contrast variation combined with chemical cross-linking/mass spectrometry on reconstituted spherical HDL","pmids":["21292766"],"confidence":"High","gaps":["Atomic-resolution structure of full-length APOA1 on HDL was not achieved","Conformational dynamics during particle remodeling were not captured"]},{"year":2013,"claim":"Stable isotope kinetic studies in human APOA1 L202P carriers quantified, for the first time, the in vivo contribution of APOA1 to tissue cholesterol efflux (~19% reduction with mutation), while revealing substantial non-HDL reverse cholesterol transport pathways.","evidence":"In vivo ¹³C₂-cholesterol infusion with three-compartment kinetic modeling and fecal sterol recovery in mutation carriers versus controls","pmids":["23650622"],"confidence":"High","gaps":["Identity of the non-HDL efflux pathways was not established","Whether the L202P mutation affects efflux capacity per particle or reduces particle number was not distinguished"]},{"year":2015,"claim":"SAXS analysis demonstrated that the N-terminal domain of full-length APOA1 integrates into the protein belt of discoidal HDL particles and accommodates cholesterol-induced bilayer thickening, clarifying its structural role beyond a separate globular domain.","evidence":"SAXS with constrained modeling of reconstituted APOA1-POPC-cholesterol discoidal particles compared to N-terminal-truncated nanodiscs","pmids":["26200866"],"confidence":"Medium","gaps":["Mutagenesis to validate N-terminal integration was not performed","Dynamic conformational changes during cholesterol loading were not time-resolved"]},{"year":2016,"claim":"Multiple non-lipid functions of APOA1 were established: modulation of Aβ1-40 transport across a reconstituted blood–brain barrier via LRP family receptors, direct interaction with dengue NS1 to neutralize lipid raft remodeling and viral infection, and selective acceptance of vitamin E via ABCA1 from intestinal enterocytes.","evidence":"In vitro BBB Transwell model with LRP inhibitors; co-IP of APOA1 with dengue NS1 and infectivity assays; polarized Caco-2 monolayer tocopherol secretion with ABCA1 induction and MTP inhibition","pmids":["27232214","33827950","23946344"],"confidence":"Medium","gaps":["In vivo relevance of APOA1-Aβ interaction for Alzheimer's disease progression was not tested","Structural basis of NS1-APOA1 interaction was not mapped","Whether selective tocopherol transfer occurs in vivo was not confirmed"]},{"year":2018,"claim":"Disulfide-locking experiments revealed that APOA1 activates LCAT through a reciprocating thumbwheel mechanism dependent on helical registry: the 5/5 registry is the predominant conformation, but a hybrid epitope spanning helices 5–7 and 3–4 of adjacent APOA1 molecules in the 5/5 registry is required for full catalytic activation.","evidence":"Engineered cysteine mutations to lock 5/2 versus 5/5 registries; LCAT cholesteryl ester formation assay and macrophage cholesterol efflux assay","pmids":["29773713"],"confidence":"High","gaps":["Atomic structure of the APOA1-LCAT complex was not resolved","How registry shifts are regulated in vivo (e.g., by lipid composition) was not determined"]},{"year":2020,"claim":"APOA1 was shown to regulate glucose homeostasis through two distinct mechanisms: suppressing glucagon secretion from pancreatic α-cells via SCARB1/PI3K/Akt/FoxO1 signaling, and enhancing skeletal muscle glucose uptake through a systemic, AMPKα2-independent mechanism.","evidence":"Pharmacological inhibitor panel (Akt, PI3K, SCARB1 blockers) in αTC1 cells with in vivo validation; recombinant APOA1 injection in wild-type and AMPKα2 kinase-dead mice with radiolabeled glucose uptake","pmids":["33086869","32244181"],"confidence":"Medium","gaps":["The systemic factor mediating muscle glucose uptake downstream of APOA1 was not identified","Whether the glucagon-suppressive effect is physiologically relevant at endogenous APOA1 concentrations was not established"]},{"year":2021,"claim":"Discovery that TRIM15 ubiquitinates APOA1 via its RING domain (recognized through the PRY/SPRY domain) for proteasomal degradation identified the first E3 ligase regulating APOA1 turnover and linked APOA1 loss to lipid droplet accumulation and pancreatic cancer metastasis via the LDLR axis.","evidence":"Mass spectrometry-identified interaction confirmed by co-IP, domain-mapping mutagenesis, ubiquitination assays, and invasion/migration assays in pancreatic cancer cells","pmids":["34311082"],"confidence":"Medium","gaps":["Whether TRIM15-mediated APOA1 degradation occurs in hepatocytes or in circulation was not tested","In vivo significance of TRIM15-APOA1 axis for lipid metabolism was not demonstrated","Ubiquitination sites on APOA1 were not mapped"]},{"year":2023,"claim":"Resolving the C-terminal conformational switch between small and large HDL particles explained size-dependent cholesterol efflux: on small HDL the flipped C-termini engage ABCA1, while LCAT-driven maturation locks C-termini onto the lipid surface, inhibiting efflux — unifying the opposing roles of LCAT activation and efflux capacity.","evidence":"Cross-linking MS and MD simulation across four HDL sizes; ABCA1-dependent efflux assays; HDL from LCAT-deficient subjects incubated with recombinant LCAT","pmids":["38018436"],"confidence":"High","gaps":["Whether the C-terminal flip is a therapeutic target for enhancing cholesterol efflux has not been tested","Structural details of the APOA1 C-terminus–ABCA1 interaction interface are not resolved"]},{"year":2024,"claim":"Identification of the FOXM1/METTL3/YTHDF2 axis regulating APOA1 mRNA stability via m6A methylation revealed an epitranscriptomic layer of APOA1 regulation, linking it to scleral fibroblast transdifferentiation in myopia.","evidence":"ChIP for FOXM1 at METTL3 promoter; Me-RIP and PAR-CLIP for m6A modification and METTL3 binding of APOA1 mRNA; knockdown/overexpression in human scleral fibroblasts under hypoxia","pmids":["38190128"],"confidence":"Medium","gaps":["Whether m6A-mediated regulation of APOA1 occurs in hepatocytes (the major source of circulating APOA1) was not examined","In vivo relevance to myopia progression was not demonstrated"]},{"year":null,"claim":"Key unresolved questions include the atomic-resolution structure of APOA1 in complex with LCAT and ABCA1, the identity of the systemic mediator of APOA1-induced muscle glucose uptake, and whether therapeutic manipulation of the C-terminal conformational switch or TRIM15-mediated degradation can enhance reverse cholesterol transport in vivo.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution APOA1-LCAT or APOA1-ABCA1 co-structure exists","Systemic mediator of APOA1 glucose uptake effect unidentified","Therapeutic relevance of TRIM15-APOA1 axis untested in vivo"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,5,6,8,17,20]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,9,17]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[1,7,19]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,2,5,7,17,20]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6]},{"term_id":"GO:0005811","term_label":"lipid droplet","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,7,9,17,19,20]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[2,7,17,19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[14]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[15]}],"complexes":["HDL particle"],"partners":["LCAT","ABCA1","MPO","SCARB1","TRIM15","SAA","LDLR"],"other_free_text":[]},"mechanistic_narrative":"APOA1, the principal structural and functional protein of high-density lipoproteins (HDL), orchestrates reverse cholesterol transport by activating lecithin:cholesterol acyltransferase (LCAT) through a helical-registry-dependent mechanism, accepting cholesterol and other lipids from peripheral cells via ABCA1-dependent efflux, and serving as a reservoir for exchangeable apolipoproteins that transfer between lipoprotein classes [PMID:4335615, PMID:4345202, PMID:29773713]. On small HDL particles, the C-termini of antiparallel APOA1 molecules adopt a flipped conformation that engages ABCA1 to promote cholesterol efflux; LCAT-driven particle maturation converts this active conformation into a lipid-adherent helical bundle that suppresses efflux capacity, and myeloperoxidase-catalyzed oxidation of APOA1 independently impairs ABCA1-dependent efflux, rendering HDL dysfunctional [PMID:38018436, PMID:15314690]. Beyond lipid transport, APOA1 suppresses glucagon secretion from pancreatic α-cells through SCARB1-mediated activation of the PI3K/Akt/FoxO1 cascade, improves glucose tolerance by increasing skeletal muscle glucose uptake independently of AMPKα2, and modulates amyloid-β transport across the blood–brain barrier via LRP family receptors [PMID:33086869, PMID:32244181, PMID:27232214]. Germline loss-of-function variants in APOA1 cause low HDL cholesterol, and position-specific amyloidogenic mutations cause hereditary apolipoprotein A-I amyloidosis (AApoAI) with organ tropism determined by the mutation location [PMID:15297675, PMID:19324996]."},"prefetch_data":{"uniprot":{"accession":"P02647","full_name":"Apolipoprotein A-I","aliases":["Apolipoprotein A1"],"length_aa":267,"mass_kda":30.8,"function":"Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P02647/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOA1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOA1","total_profiled":1310},"omim":[{"mim_id":"620657","title":"AMYLOIDOSIS, HEREDITARY SYSTEMIC 3; AMYLD3","url":"https://www.omim.org/entry/620657"},{"mim_id":"620112","title":"APOA1 ANTISENSE RNA, NONCODING; APOA1AS","url":"https://www.omim.org/entry/620112"},{"mim_id":"620058","title":"FAMILIAL APOLIPOPROTEIN GENE CLUSTER DELETION SYNDROME","url":"https://www.omim.org/entry/620058"},{"mim_id":"619836","title":"HYPOALPHALIPOPROTEINEMIA, PRIMARY, 2, INTERMEDIATE","url":"https://www.omim.org/entry/619836"},{"mim_id":"618882","title":"IMERSLUND-GRASBECK SYNDROME 2; IGS2","url":"https://www.omim.org/entry/618882"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":20151.0}],"url":"https://www.proteinatlas.org/search/APOA1"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P02647","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02647","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02647-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02647-F1-predicted_aligned_error_v6.png","plddt_mean":73.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOA1","jax_strain_url":"https://www.jax.org/strain/search?query=APOA1"},"sequence":{"accession":"P02647","fasta_url":"https://rest.uniprot.org/uniprotkb/P02647.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02647/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02647"}},"corpus_meta":[{"pmid":"25249180","id":"PMC_25249180","title":"The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25249180","citation_count":138,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33591433","id":"PMC_33591433","title":"APOA1: a Protein with Multiple Therapeutic Functions.","date":"2021","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/33591433","citation_count":137,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11756058","id":"PMC_11756058","title":"Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner: the Framingham Study.","date":"2002","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/11756058","citation_count":117,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15767855","id":"PMC_15767855","title":"The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk.","date":"2005","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/15767855","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36063649","id":"PMC_36063649","title":"Leveraging knowledge of HDLs major protein ApoA1: Structure, function, mutations, and potential therapeutics.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36063649","citation_count":99,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19324996","id":"PMC_19324996","title":"Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene.","date":"2009","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/19324996","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14962947","id":"PMC_14962947","title":"In-depth haplotype analysis of ABCA1 gene polymorphisms in relation to plasma ApoA1 levels and myocardial infarction.","date":"2004","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14962947","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27183204","id":"PMC_27183204","title":"ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease.","date":"2016","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27183204","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2903847","id":"PMC_2903847","title":"DNA polymorphism haplotypes of the human apolipoprotein APOA1-APOC3-APOA4 gene cluster.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2903847","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29773713","id":"PMC_29773713","title":"A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL.","date":"2018","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/29773713","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21131532","id":"PMC_21131532","title":"D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma.","date":"2010","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/21131532","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21496341","id":"PMC_21496341","title":"Identification of Apo-A1 as a biomarker for early diagnosis of bladder transitional cell carcinoma.","date":"2011","source":"Proteome science","url":"https://pubmed.ncbi.nlm.nih.gov/21496341","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30941792","id":"PMC_30941792","title":"KCNQ1OT1, HIF1A-AS2 and APOA1-AS are promising novel biomarkers for diagnosis of coronary artery disease.","date":"2019","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30941792","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24661883","id":"PMC_24661883","title":"Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24661883","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9125316","id":"PMC_9125316","title":"Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of apo A-I and HDL-cholesterol.","date":"1996","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/9125316","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20399916","id":"PMC_20399916","title":"Reduced plasma APOA1 level is associated with gastric tumor growth in MKN45 mouse xenograft model.","date":"2010","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/20399916","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21875686","id":"PMC_21875686","title":"Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21875686","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27232214","id":"PMC_27232214","title":"Modulation of Amyloid-β1-40 Transport by ApoA1 and ApoJ Across an in vitro Model of the Blood-Brain Barrier.","date":"2016","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/27232214","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32456156","id":"PMC_32456156","title":"The Positive Side of the Alzheimer's Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1.","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32456156","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19592705","id":"PMC_19592705","title":"Effects of variations in the APOA1/C3/A4/A5 gene cluster on different parameters of postprandial lipid metabolism in healthy young men.","date":"2010","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/19592705","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26491253","id":"PMC_26491253","title":"Decreased expression of the APOA1-APOC3-APOA4 gene cluster is associated with risk of Alzheimer's disease.","date":"2015","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26491253","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34311082","id":"PMC_34311082","title":"TRIM15 promotes the invasion and metastasis of pancreatic cancer cells by mediating APOA1 ubiquitination and degradation.","date":"2021","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/34311082","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21292766","id":"PMC_21292766","title":"The low resolution structure of ApoA1 in spherical high density lipoprotein revealed by small angle neutron scattering.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21292766","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15681655","id":"PMC_15681655","title":"Kinetic stabilization and fusion of apolipoprotein A-2:DMPC disks: comparison with apoA-1 and apoC-1.","date":"2005","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15681655","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12556235","id":"PMC_12556235","title":"The study of APOA1, APOC3 and APOA4 variability in healthy ageing people reveals another paradox in the oldest old subjects.","date":"2003","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12556235","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15108119","id":"PMC_15108119","title":"The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.","date":"2004","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15108119","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14636880","id":"PMC_14636880","title":"APOA1 related amyloidosis: a case report and literature review.","date":"2003","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14636880","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24969553","id":"PMC_24969553","title":"Identification of ApoA1, HPX and POTEE genes by omic analysis in breast cancer.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24969553","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23209431","id":"PMC_23209431","title":"Population-based resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23209431","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26824674","id":"PMC_26824674","title":"Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26824674","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33827950","id":"PMC_33827950","title":"ApoA1 Neutralizes Proinflammatory Effects of Dengue Virus NS1 Protein and Modulates Viral Immune Evasion.","date":"2021","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/33827950","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2496752","id":"PMC_2496752","title":"Interaction of ApoA-1 and ApoE-3 with triglyceride-phospholipid emulsions containing increasing cholesterol concentrations. Model of triglyceride-rich nascent and remnant lipoproteins.","date":"1989","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2496752","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21443680","id":"PMC_21443680","title":"Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels.","date":"2011","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21443680","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18206649","id":"PMC_18206649","title":"APOA1/C3/A5 haplotype and risk of hypertriglyceridemia in Taiwanese.","date":"2007","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18206649","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18801202","id":"PMC_18801202","title":"Genetic studies on the APOA1-C3-A5 gene cluster in Asian Indians with premature coronary artery disease.","date":"2008","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/18801202","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16710093","id":"PMC_16710093","title":"Evidence for consistent intragenic and intergenic interactions between SNP effects in the APOA1/C3/A4/A5 gene cluster.","date":"2006","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/16710093","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26388776","id":"PMC_26388776","title":"HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis.","date":"2015","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26388776","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32244181","id":"PMC_32244181","title":"ApoA-1 improves glucose tolerance by increasing glucose uptake into heart and skeletal muscle independently of AMPKα2.","date":"2020","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32244181","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38018436","id":"PMC_38018436","title":"Flipped C-Terminal Ends of APOA1 Promote ABCA1-Dependent Cholesterol Efflux by Small HDLs.","date":"2023","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/38018436","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30328580","id":"PMC_30328580","title":"Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.","date":"2018","source":"Virologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/30328580","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26617857","id":"PMC_26617857","title":"Genetic association of the ApoB and ApoA1 gene polymorphisms with the risk for alcohol-induced osteonecrosis of femoral head.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26617857","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31779197","id":"PMC_31779197","title":"LCAT, ApoD, and ApoA1 Expression and Review of Cholesterol Deposition in the Cornea.","date":"2019","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/31779197","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29150341","id":"PMC_29150341","title":"Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1.","date":"2017","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/29150341","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22675253","id":"PMC_22675253","title":"Associations of polymorphisms in the apolipoprotein APOA1-C3-A5 gene cluster with acute coronary syndrome.","date":"2012","source":"Journal of biomedicine & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/22675253","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24926085","id":"PMC_24926085","title":"APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival.","date":"2014","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24926085","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32071782","id":"PMC_32071782","title":"Long noncoding RNAs APOA1-AS, IFNG-AS1, RMRP and their related biomolecules in Egyptian patients with relapsing-remitting multiple sclerosis: Relation to disease activity and patient disability.","date":"2019","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/32071782","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15044382","id":"PMC_15044382","title":"Haplotypes in the APOA1-C3-A4-A5 gene cluster affect plasma lipids in both humans and baboons.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15044382","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30128915","id":"PMC_30128915","title":"Role of long non-coding RNAs expression (ANRIL, NOS3-AS, and APOA1-AS) in development of atherosclerosis in Egyptian systemic lupus erythematosus patients.","date":"2018","source":"Clinical rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/30128915","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25650312","id":"PMC_25650312","title":"Design and synthesis of a novel candidate compound NTI-007 targeting sodium taurocholate cotransporting polypeptide [NTCP]-APOA1-HBx-Beclin1-mediated autophagic pathway in HBV therapy.","date":"2015","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25650312","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32681583","id":"PMC_32681583","title":"Alzheimer's disease in the gut-Major changes in the gut of 5xFAD model mice with ApoA1 as potential key player.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32681583","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15962178","id":"PMC_15962178","title":"APOA1/C3/A4 gene cluster variability and lipid levels in Brazilian children.","date":"2005","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/15962178","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23650622","id":"PMC_23650622","title":"In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1.","date":"2013","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23650622","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16403951","id":"PMC_16403951","title":"APOA1-75 G to A substitution associated with severe forms of CAD, lower levels of HDL and apoA-I among northern Indians.","date":"2005","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/16403951","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34382908","id":"PMC_34382908","title":"LncRNA APOA1-AS facilitates proliferation and migration and represses apoptosis of VSMCs through TAF15-mediated SMAD3 mRNA stabilization.","date":"2021","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/34382908","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35479414","id":"PMC_35479414","title":"Selective activation of ABCA1/ApoA1 signaling in the V1 by magnetoelectric stimulation ameliorates depression via regulation of synaptic plasticity.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/35479414","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23989729","id":"PMC_23989729","title":"Plasma lipids, genetic variants near APOA1, and the risk of infantile hypertrophic pyloric stenosis.","date":"2013","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/23989729","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23946344","id":"PMC_23946344","title":"Vitamin E secretion by Caco-2 monolayers to APOA1, but not to HDL, is vitamer selective.","date":"2013","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/23946344","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34141821","id":"PMC_34141821","title":"Targeting the Apoa1 locus for liver-directed gene therapy.","date":"2021","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/34141821","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24689997","id":"PMC_24689997","title":"The apoB/apoA1 ratio predicts future cardiovascular events in patients with rheumatoid arthritis.","date":"2014","source":"Scandinavian journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/24689997","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26200866","id":"PMC_26200866","title":"Small-angle X-ray scattering of the cholesterol incorporation into human ApoA1-POPC discoidal particles.","date":"2015","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/26200866","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22323901","id":"PMC_22323901","title":"Polymorphism in apoA1 Influences High-Density Lipoprotein Cholesterol Levels but Is Not a Major Risk Factor of Alzheimer's Disease.","date":"2012","source":"Dementia and geriatric cognitive disorders extra","url":"https://pubmed.ncbi.nlm.nih.gov/22323901","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15657615","id":"PMC_15657615","title":"Polymorphisms in APOA1 and LPL genes are statistically independently associated with fasting TG in men with CAD.","date":"2005","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/15657615","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24376512","id":"PMC_24376512","title":"Gene-gene combination effect and interactions among ABCA1, APOA1, SR-B1, and CETP polymorphisms for serum high-density lipoprotein-cholesterol in the Japanese population.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24376512","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18597093","id":"PMC_18597093","title":"Increase levels of apo-A1 and apo B are associated in knee osteoarthritis: lack of association with VEGF-460 T/C and +405 C/G polymorphisms.","date":"2008","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/18597093","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22246850","id":"PMC_22246850","title":"The relationship between high-sensitivity C-reactive protein and ApoB, ApoB/ApoA1 ratio in general population of China.","date":"2012","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/22246850","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22306989","id":"PMC_22306989","title":"ApoA1: mimetic peptide reverses adipocyte dysfunction in vivo and in vitro via an increase in heme oxygenase (HO-1) and Wnt10b.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22306989","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24508624","id":"PMC_24508624","title":"Gender-specific associations of the APOA1 -75G>A polymorphism with several metabolic syndrome components in Turkish adults.","date":"2014","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24508624","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27171122","id":"PMC_27171122","title":"APOA5 and APOA1 polymorphisms are associated with triglyceride levels in Mexican children.","date":"2016","source":"Pediatric obesity","url":"https://pubmed.ncbi.nlm.nih.gov/27171122","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38190128","id":"PMC_38190128","title":"FOXM1 Participates in Scleral Remodeling in Myopia by Upregulating APOA1 Expression Through METTL3/YTHDF2.","date":"2024","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/38190128","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31412738","id":"PMC_31412738","title":"Serum apoA1 (Apolipoprotein A-1), Insulin Resistance, and the Risk of Gestational Diabetes Mellitus in Human Pregnancy-Brief Report.","date":"2019","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31412738","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27734225","id":"PMC_27734225","title":"Increased expression of ApoA1 after neuronal injury may be beneficial for healing.","date":"2016","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27734225","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29859275","id":"PMC_29859275","title":"Role of rs670 variant of APOA1 gene on lipid profile, insulin resistance and adipokine levels in obese subjects after weight loss with a dietary intervention.","date":"2018","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/29859275","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23829168","id":"PMC_23829168","title":"The dyslipidemia-associated SNP on the APOA1/C3/A5 gene cluster predicts post-surgery poor outcome in Taiwanese breast cancer patients: a 10-year follow-up study.","date":"2013","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23829168","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17378725","id":"PMC_17378725","title":"Polymorphisms in the APOA1/C3/A4/A5 gene cluster and cholesterol responsiveness to dietary change.","date":"2007","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17378725","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34226567","id":"PMC_34226567","title":"High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia.","date":"2021","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34226567","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23754445","id":"PMC_23754445","title":"Controlling the diameter, monodispersity, and solubility of ApoA1 nanolipoprotein particles using telodendrimer chemistry.","date":"2013","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/23754445","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30467071","id":"PMC_30467071","title":"Role of rs670 variant of APOA1 gene on metabolic response after a high fat vs. a low fat hypocaloric diets in obese human subjects.","date":"2018","source":"Journal of diabetes and its complications","url":"https://pubmed.ncbi.nlm.nih.gov/30467071","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34555726","id":"PMC_34555726","title":"Hsa_circ_0088212-mediated miR-520 h/APOA1 axis inhibits osteosarcoma progression.","date":"2021","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34555726","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23690001","id":"PMC_23690001","title":"Genetic association between APOA1 and APOD polymorphisms and Alzheimer's disease in a Japanese population.","date":"2013","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/23690001","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24081495","id":"PMC_24081495","title":"Genetic polymorphisms in the APOA1 gene and their relationship with serum HDL cholesterol levels.","date":"2013","source":"Lipids","url":"https://pubmed.ncbi.nlm.nih.gov/24081495","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28969676","id":"PMC_28969676","title":"Interactions of six SNPs in APOA1 gene and types of obesity on low HDL-C disease in Xinjiang pastoral area of China.","date":"2017","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/28969676","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33086869","id":"PMC_33086869","title":"HDL (High-Density Lipoprotein) and ApoA-1 (Apolipoprotein A-1) Potentially Modulate Pancreatic α-Cell Glucagon Secretion.","date":"2020","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33086869","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20480398","id":"PMC_20480398","title":"APOA1/A5 variants and haplotypes as a risk factor for obesity and better lipid profiles in a Brazilian Elderly Cohort.","date":"2010","source":"Lipids","url":"https://pubmed.ncbi.nlm.nih.gov/20480398","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27240838","id":"PMC_27240838","title":"A case report of hereditary apolipoprotein A-I amyloidosis associated with a novel APOA1 mutation and variable phenotype.","date":"2016","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27240838","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30744100","id":"PMC_30744100","title":"Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30744100","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33244380","id":"PMC_33244380","title":"Introducing APOA1 as a key protein in COVID-19 infection: a bioinformatics approach.","date":"2020","source":"Gastroenterology and hepatology from bed to bench","url":"https://pubmed.ncbi.nlm.nih.gov/33244380","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31165758","id":"PMC_31165758","title":"Association of BUD13-ZNF259-APOA5-APOA1-SIK3 cluster polymorphism in 11q23.3 and structure of APOA5 with increased plasma triglyceride levels in a Korean population.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31165758","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17727676","id":"PMC_17727676","title":"Effect of the combination of the variants -75G/A APOA1 and Trp64Arg ADRB3 on the risk of type 2 diabetes (DM2).","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17727676","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15488874","id":"PMC_15488874","title":"A prospective study of the APOA1 XmnI and APOC3 SstI polymorphisms in the APOA1/C3/A4 gene cluster and risk of incident myocardial infarction in men.","date":"2004","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/15488874","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22119776","id":"PMC_22119776","title":"Apolipoprotein A-1 (apoA-1) deposition in, and release from, the enterocyte brush border: a possible role in transintestinal cholesterol efflux (TICE)?","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22119776","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23459084","id":"PMC_23459084","title":"Central obesity in males affected by a dyslipidemia-associated genetic polymorphism on APOA1/C3/A4/A5 gene cluster.","date":"2013","source":"Nutrition & diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/23459084","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18565099","id":"PMC_18565099","title":"Cathepsin S genotypes are associated with Apo-A1 and HDL-cholesterol in lean and obese French populations.","date":"2008","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18565099","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23169576","id":"PMC_23169576","title":"ApoA-1 mimetic restores adiponectin expression and insulin sensitivity independent of changes in body weight in female obese mice.","date":"2012","source":"Nutrition & diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/23169576","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29747660","id":"PMC_29747660","title":"Association of the APOA1 rs964184 SNP and serum lipid traits in the Chinese Maonan and Han populations.","date":"2018","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/29747660","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30004304","id":"PMC_30004304","title":"High Level of APOA1 in Blood and Maternal Fetal Interface Is Associated With Early Miscarriage.","date":"2018","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/30004304","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30631647","id":"PMC_30631647","title":"Functional polymorphisms of the APOA1/C3/A4/A5-ZPR1-BUD13 gene cluster are associated with dyslipidemia in a sex-specific pattern.","date":"2019","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/30631647","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21576418","id":"PMC_21576418","title":"Comparison of lipid profiles with APOA1 MspI polymorphism in obese children with hyperlipidemia.","date":"2011","source":"In vivo (Athens, Greece)","url":"https://pubmed.ncbi.nlm.nih.gov/21576418","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2108924","id":"PMC_2108924","title":"Apolipoprotein A1 Baltimore (Arg10----Leu), a new ApoA1 variant.","date":"1990","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2108924","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27105909","id":"PMC_27105909","title":"Heparin interactions with apoA1 and SAA in inflammation-associated HDL.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27105909","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35858961","id":"PMC_35858961","title":"APOA1 mRNA and protein in kidney renal clear cell carcinoma correlate with the disease outcome.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35858961","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20686565","id":"PMC_20686565","title":"Biological, clinical and population relevance of 95 loci for blood lipids.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20686565","citation_count":2873,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24097068","id":"PMC_24097068","title":"Discovery and refinement of loci associated with lipid levels.","date":"2013","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24097068","citation_count":2409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21378990","id":"PMC_21378990","title":"Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21378990","citation_count":1493,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18193043","id":"PMC_18193043","title":"Newly identified loci that influence lipid concentrations and risk of coronary artery disease.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18193043","citation_count":1310,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18193044","id":"PMC_18193044","title":"Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18193044","citation_count":1130,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19060906","id":"PMC_19060906","title":"Common variants at 30 loci contribute to polygenic dyslipidemia.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19060906","citation_count":1113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15297675","id":"PMC_15297675","title":"Multiple rare alleles contribute to low plasma levels of HDL cholesterol.","date":"2004","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15297675","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27477018","id":"PMC_27477018","title":"TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia.","date":"2016","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/27477018","citation_count":724,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19060911","id":"PMC_19060911","title":"Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19060911","citation_count":695,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"4335615","id":"PMC_4335615","title":"A protein cofactor of lecithin:cholesterol acyltransferase.","date":"1972","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/4335615","citation_count":694,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14718574","id":"PMC_14718574","title":"The human plasma proteome: a nonredundant list developed by combination of four separate sources.","date":"2004","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/14718574","citation_count":658,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14630798","id":"PMC_14630798","title":"Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14630798","citation_count":616,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16968945","id":"PMC_16968945","title":"Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.","date":"2006","source":"Pharmacological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16968945","citation_count":579,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15314690","id":"PMC_15314690","title":"Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.","date":"2004","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15314690","citation_count":575,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19074352","id":"PMC_19074352","title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.","date":"2008","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/19074352","citation_count":573,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29518356","id":"PMC_29518356","title":"TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function.","date":"2018","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/29518356","citation_count":571,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"4345202","id":"PMC_4345202","title":"Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man.","date":"1973","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/4345202","citation_count":514,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12665801","id":"PMC_12665801","title":"Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.","date":"2003","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/12665801","citation_count":485,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25910212","id":"PMC_25910212","title":"Widespread macromolecular interaction perturbations in human genetic disorders.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25910212","citation_count":454,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12050338","id":"PMC_12050338","title":"Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.","date":"2002","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12050338","citation_count":451,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55746,"output_tokens":4100,"usd":0.114369},"stage2":{"model":"claude-opus-4-6","input_tokens":7563,"output_tokens":2725,"usd":0.15891},"total_usd":0.668487,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":68257,"output_tokens":7188,"usd":0.156296},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":10850,"output_tokens":4201,"usd":0.238912}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"APOA1 uses a reciprocating thumbwheel-like mechanism to activate LCAT on HDL: most APOA1 adopts a 5/5 helical registry on discoidal HDL, but a fraction adopts a 5/2 registry; locking APOA1 in the 5/2 registry by engineered disulfide bonds impairs LCAT cholesteryl esterification activity without affecting LCAT binding, and full LCAT activity requires a hybrid epitope composed of helices 5-7 on one APOA1 molecule and helices 3-4 on the other.\",\n      \"method\": \"Cysteine mutagenesis to lock disulfide bonds in specific registries, LCAT activity assay, cholesterol efflux assay, chemical cross-linking\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with mutagenesis, multiple orthogonal functional assays in a single rigorous study\",\n      \"pmids\": [\"29773713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In small HDL particles, the C-termini of the two antiparallel APOA1 molecules are 'flipped' off the lipid surface, enabling productive engagement with ABCA1 transporter and enhanced cholesterol efflux capacity (CEC); in larger HDL particles, C-termini form a helical bundle that adheres to the lipid surface and cannot interact with ABCA1. LCAT activity converts small discoidal HDL to larger particles and markedly inhibits CEC.\",\n      \"method\": \"Tandem mass spectrometric analysis of chemically cross-linked peptides, molecular dynamics simulations, reconstituted HDL model system, CEC assay with LCAT-deficient subjects, calibrated ion mobility analysis\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (cross-linking MS, MD simulation, physiological validation in LCAT-deficient humans) in a single study\",\n      \"pmids\": [\"38018436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In spherical HDL (sHDL), three APOA1 chains form a hollow protein shell that cradles a central compact lipid core, most consistent with a helical dimer plus hairpin (HdHp) global architecture as determined by small-angle neutron scattering with contrast variation, cross-linking, and mass spectrometry.\",\n      \"method\": \"Small-angle neutron scattering (SANS) with contrast variation, chemical cross-linking, mass spectrometry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural determination with orthogonal cross-linking/MS validation\",\n      \"pmids\": [\"21292766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The N-terminal domain of APOA1 is not a separate globular domain in discoidal APOA1-POPC-cholesterol particles but is an integrated part of the protein belt; upon cholesterol incorporation it allows bilayer thickness to increase while maintaining a flat bilayer, facilitating optimal lipid packing.\",\n      \"method\": \"Small-angle X-ray scattering (SAXS) with molecular constrained data modeling, comparison of full-length APOA1 vs. N-terminal truncated nanodisc system\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — SAXS structural analysis, single lab, single method\",\n      \"pmids\": [\"26200866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In vivo tissue cholesterol efflux is reduced by ~19% in carriers of the L202P mutation in APOA1, demonstrating that APOA1/HDL contributes to efflux of tissue cholesterol in humans; however, residual efflux and unaffected fecal sterol excretion indicate significant non-HDL pathways also contribute.\",\n      \"method\": \"13C2-cholesterol isotope infusion, three-compartment SAAM-II pharmacokinetic modeling, fecal sterol measurement in APOA1 mutation carriers vs. controls\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean human genetic model with stable isotope tracer in vivo, single study\",\n      \"pmids\": [\"23650622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRIM15 E3 ubiquitin ligase binds APOA1 through its PRY/SPRY domain and promotes APOA1 polyubiquitination via its RING domain, leading to APOA1 degradation, enhanced lipid anabolism, lipid droplet accumulation, and promotion of pancreatic cancer cell invasion/migration via the APOA1-LDLR axis.\",\n      \"method\": \"Mass spectrometry interactome, Co-IP, TRIM15 knockdown/overexpression, ubiquitination assay, invasion/migration assays\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — reciprocal Co-IP, MS identification, ubiquitination assay, functional rescue; single lab\",\n      \"pmids\": [\"34311082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DENV nonstructural protein NS1 interacts with APOA1; APOA1-mediated lipid raft depletion inhibits DENV attachment to the cell surface, and APOA1 neutralizes NS1-induced cell activation and NS1-mediated enhancement of DENV infection.\",\n      \"method\": \"Co-IP/binding assay between NS1 and ApoA1, lipid raft depletion assay, DENV infection assay with ApoA1 treatment, ApoA1 mimetic peptide 4F experiments\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — direct binding demonstration with functional infection assays, single lab\",\n      \"pmids\": [\"33827950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Recombinant APOA1 improves glucose tolerance and increases glucose clearance into skeletal and heart muscle in vivo independently of AMPKα2 activity; the effect requires systemic factors as ApoA1 fails to stimulate glucose uptake in isolated muscle ex vivo.\",\n      \"method\": \"Injection of recombinant human ApoA1 into high-fat diet-fed wild-type and AMPKα2 kinase-dead mice, glucose tolerance test, 2-deoxyglucose uptake tracer, isolated muscle ex vivo glucose uptake assay\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic epistasis (kinase-dead AMPKα2 mice) with in vivo and ex vivo functional assays; single lab\",\n      \"pmids\": [\"32244181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HDL and ApoA-1 suppress glucagon expression and secretion from pancreatic α-cells via binding to receptor SCARB-1 (SR-BI) and activating the PI3K/Akt/FoxO1 signaling cascade; pharmacological inhibition of Akt, PI3K, or SCARB-1 blocks the ApoA1/HDL-mediated suppression.\",\n      \"method\": \"αTC1 clone 6 cell treatment with HDL or recombinant ApoA-1, glucagon secretion/expression assays, Akt/FoxO1 phosphorylation western blot, pharmacological inhibitors (Akt inhibitor VIII, LY294002, BLT-1), in vivo mouse ApoA-1 injection\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissection with multiple inhibitors and in vivo validation; single lab\",\n      \"pmids\": [\"33086869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ApoA1 promotes wound healing after neuronal injury by activating the ERK pathway and inducing actin polymerization in a neuroblastoma injury model; ApoA1 expression increases sharply in the secondary phase of spinal cord injury.\",\n      \"method\": \"Scratch wound healing assay in neuroblastoma cells with ApoA1 treatment, ERK pathway activation assay, actin polymerization assay, temporal protein expression analysis in spinal cord injury model\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, limited mechanistic follow-up, no pathway genetic validation\",\n      \"pmids\": [\"27734225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ApoA1 modulates Aβ1-40 transport across the blood-brain barrier (BBB): ApoA1 in the apical (blood) compartment mobilizes Aβ1-40 from the basolateral (brain) side, while ApoA1 complexed to Aβ1-40 does not enhance efflux; ApoA1 crosses the BBB via a mechanism involving the LDL receptor-related protein family.\",\n      \"method\": \"In vitro BBB model (primary cerebral endothelial cells on Matrigel-coated Transwells), fluorescently labeled Aβ1-40 transport assay, LRP inhibitor experiments\",\n      \"journal\": \"Journal of Alzheimer's disease : JAD\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — in vitro model, single lab, mechanistic pathway partially characterized\",\n      \"pmids\": [\"27232214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ApoA-1 secreted apically by intestinal enterocytes deposits in the brush border where it associates with cholesterol in lipid raft microdomains; brush border-deposited ApoA1 is released by bile/taurocholate and proposed to mediate transintestinal cholesterol efflux (TICE).\",\n      \"method\": \"Immunomicroscopy, subcellular fractionation, immunoisolation of microvillar ApoA1, cholesterol detection, detergent-resistant membrane analysis, taurocholate release assay in porcine small intestine\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — direct localization with functional hypothesis but efflux role not directly demonstrated in vivo\",\n      \"pmids\": [\"22119776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Heparin interacts with ApoA1 and SAA simultaneously on HDL isolated from inflamed mice; mass spectrometry of chemically cross-linked HDL-SAA particles detected multiple cross-links between ApoA1 and SAA indicating close proximity (within 25 Å) on the HDL surface, providing a structural basis for simultaneous heparin binding.\",\n      \"method\": \"Gel electrophoresis, chemical cross-linking, mass spectrometry of cross-linked peptides, HDL isolation from inflamed mice\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — cross-linking MS provides structural proximity data; single lab, no functional consequence directly tested\",\n      \"pmids\": [\"27105909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ABCA1-mediated secretion of vitamin E (tocopherols) from intestinal Caco-2 cells to APOA1 is vitamer-selective: α- and γ-tocopherols are secreted more efficiently than δ-tocopherol via ABCA1, while the APOB-dependent pathway shows no vitamer selectivity.\",\n      \"method\": \"Polarized Caco-2 monolayer transport assay, ABCA1 induction by LXR agonist T0901317, MTP inhibitor BMS201038, SR-BI blocking antibody, radiolabeled tocopherol secretion measurement\",\n      \"journal\": \"The Journal of nutrition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological interventions in a well-characterized cell system with quantitative readout; single lab\",\n      \"pmids\": [\"23946344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FOXM1 represses METTL3 transcription by binding the METTL3 promoter (ChIP), reducing m6A methylation of APOA1 mRNA; reduced m6A decreases YTHDF2-dependent degradation of APOA1 mRNA, thereby stabilizing and increasing APOA1 expression in hypoxia-induced scleral fibroblasts, promoting myofibroblast transdifferentiation changes associated with myopia.\",\n      \"method\": \"ChIP, Me-RIP (m6A immunoprecipitation), PAR-CLIP, RT-qPCR, western blot, loss/gain of function experiments in hypoxia-induced human scleral fibroblasts\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal epigenetic methods (ChIP, Me-RIP, PAR-CLIP) with functional rescue experiments; single lab\",\n      \"pmids\": [\"38190128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"ApoA-1 binds to triglyceride-phospholipid emulsion particles in a saturable manner (Kd ~7.4×10⁻⁷ M); cholesterol saturation of particles (>3.7%) sharply decreases apoA-1 binding capacity without changing affinity, suggesting that high cholesterol content of lipoprotein remnants impairs apoA-1 redistribution.\",\n      \"method\": \"In vitro binding assay to lipid emulsion particles with increasing cholesterol content, Scatchard analysis, electron microscopy\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution binding assay with quantitative kinetic parameters; single lab\",\n      \"pmids\": [\"2496752\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOA1, the major protein of HDL, wraps around a lipid bilayer disk in an antiparallel double-belt configuration and can adopt distinct helical registries (5/5 vs. 5/2) that control LCAT activation through a thumbwheel mechanism; in small HDL particles its C-termini flip off the lipid surface to engage ABCA1 and drive cholesterol efflux, while larger particles sequester the C-termini in a helical bundle that limits ABCA1 interaction; beyond cholesterol transport, APOA1 activates signaling cascades (PI3K/Akt/FoxO1 in α-cells, ERK/actin in neurons) via receptor SCARB-1 and ABCA1, and is subject to TRIM15-mediated ubiquitination and proteasomal degradation that regulates its intracellular levels and downstream lipid metabolism.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper and extract discoveries only from KEEP papers.\n\n**Classification decisions:**\n- Papers 13, 46, 48, 54 (APOA1-AS lncRNA) → EXCLUDE (alt-locus product, case B)\n- Papers 78 (circ_0088212/APOA1 axis - the circRNA is the subject, APOA1 is downstream target) → KEEP (APOA1 function is described)\n- Papers 1 (BET bromodomain inhibitor drug discovery) → EXCLUDE (not about APOA1 mechanism)\n- Papers from additional list: Large GWAS papers → EXCLUDE (no mechanistic findings about APOA1)\n- Papers 3, 8, 10, 11, 12, 13 (interactome networks) → EXCLUDE (no APOA1-specific mechanism)\n- All papers describing APOA1 protein function mechanistically → KEEP\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1972,\n      \"finding\": \"APOA1 acts as a protein cofactor (activator) of lecithin:cholesterol acyltransferase (LCAT), stimulating the esterification of cholesterol in plasma.\",\n      \"method\": \"In vitro biochemical reconstitution assay measuring LCAT activity in the presence and absence of apolipoprotein fractions\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original reconstitution assay, foundational finding with 694 citations and independently replicated across decades\",\n      \"pmids\": [\"4335615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1973,\n      \"finding\": \"APOA1-containing high-density lipoproteins donate apolipoprotein C activators (lipoprotein lipase activators) to chylomicrons during alimentary lipemia, demonstrating that APOA1/HDL particles serve as a reservoir for exchangeable apolipoproteins that transfer between lipoprotein classes during triglyceride metabolism.\",\n      \"method\": \"In vivo metabolic study in humans measuring apolipoprotein distribution across lipoprotein fractions before and after fat meals; polyacrylamide gel electrophoresis and biochemical quantification\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo quantitative measurement with 514 citations; directly demonstrates apolipoprotein exchange between lipoprotein classes\",\n      \"pmids\": [\"4345202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"APOA1 is a selective target for myeloperoxidase (MPO)-catalyzed nitration and chlorination in vivo; MPO binds directly to APOA1 on HDL particles, and MPO-mediated oxidative modification of APOA1 selectively inhibits ABCA1-dependent cholesterol efflux from macrophages, converting HDL into a dysfunctional, proatherogenic form.\",\n      \"method\": \"Cross-immunoprecipitation of MPO with apoA-I in plasma; mass spectrometry quantification of nitrotyrosine and chlorotyrosine in apoA-I from serum and atherosclerotic lesions; ABCA1-dependent [³H]-cholesterol efflux assays from macrophages; identification of MPO-apoA-I contact site\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (co-IP, MS, functional efflux assay, lesion analysis), 575 citations, strong mechanistic evidence\",\n      \"pmids\": [\"15314690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Rare nonsynonymous variants in APOA1 (along with ABCA1 and LCAT) are significantly more common in individuals with low HDL-C (<5th percentile) than high HDL-C (>95th percentile), and most such variants are functionally important as demonstrated by biochemical studies, establishing that rare loss-of-function alleles in APOA1 collectively contribute substantially to low plasma HDL levels in the general population.\",\n      \"method\": \"Population-based resequencing of APOA1, ABCA1, and LCAT; biochemical functional studies of identified variants\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — resequencing combined with functional biochemical validation; 829 citations; replicated in independent population\",\n      \"pmids\": [\"15297675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Amyloidogenic APOA1 mutations cluster in two hot-spot regions (residues 50–93 and 170–178) of the mature protein; mutations in residues 1–75 predominantly cause hepatic and renal amyloidosis, while mutations in residues 173–178 cause cardiac, laryngeal, and cutaneous amyloidosis, establishing a genotype–phenotype correlation linking mutation position to organ tropism of AApoAI amyloid deposition.\",\n      \"method\": \"Sequencing of APOA1 germline mutations in patients with biopsy-confirmed amyloidosis; Congo red staining with polarized light; immunohistochemistry with anti-apoAI antibodies; identification of three novel frameshift and missense mutations\",\n      \"journal\": \"The Journal of molecular diagnostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct sequencing with pathological confirmation across multiple patients; supported by prior literature on 16 total mutations establishing hot-spot pattern\",\n      \"pmids\": [\"19324996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"On spherical HDL (sHDL), three APOA1 chains adopt a helical dimer with hairpin (HdHp) architecture as the most consistent global structure, forming a hollow protein shell that cradles a central compact lipid core, as determined by small-angle neutron scattering with contrast variation combined with chemical cross-linking and mass spectrometry.\",\n      \"method\": \"Small-angle neutron scattering (SANS) with contrast variation on reconstituted sHDL; chemical cross-linking followed by mass spectrometry to discriminate among three structural models (HdHp, 3Hp, iT)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — solution structural method with orthogonal cross-linking/MS validation; replicated aspects consistent with prior structural studies\",\n      \"pmids\": [\"21292766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"APOA1 synthesized by small intestinal enterocytes is secreted apically and deposits in the brush border membrane, where it associates with cholesterol in detergent-resistant lipid raft microdomains; bile salts (taurocholate) efficiently release brush-border APOA1 at sub-solubilizing concentrations, and this apically localized APOA1 is proposed to mediate transintestinal cholesterol efflux (TICE) into the gut lumen.\",\n      \"method\": \"Immunomicroscopy and subcellular fractionation of porcine small intestine; immunoisolation of microvillar vesicles; cholesterol detection in apoA-1 immunoisolates; detergent-resistant membrane (DRM) fractionation; treatment with phospholipase C, trypsin, bile salts; comparison with aminopeptidase N as transmembrane control\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization with functional fractionation and release experiments; single lab, but multiple orthogonal methods\",\n      \"pmids\": [\"22119776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In vivo tissue cholesterol efflux (TCE) is reduced by 19% in carriers of the L202P mutation in APOA1 compared to controls with normal HDL-C, demonstrating that functional APOA1 directly mediates cholesterol efflux from peripheral tissues in humans; residual TCE and unaffected fecal sterol excretion indicate that non-HDL pathways also substantially contribute to reverse cholesterol transport.\",\n      \"method\": \"In vivo stable isotope infusion of ¹³C₂-cholesterol in APOA1 L202P mutation carriers and controls; three-compartment SAAM-II kinetic modeling of plasma and erythrocyte cholesterol enrichment; fecal ¹³C recovery measurement\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo stable isotope kinetic study with defined genetic model and quantitative readout; directly establishes APOA1 role in tissue cholesterol efflux in humans\",\n      \"pmids\": [\"23650622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The N-terminal domain of full-length APOA1 participates as an integrated part of the protein belt (not as a separate globular domain) stabilizing discoidal APOA1-POPC-cholesterol particles; upon cholesterol incorporation, the N-terminal domain allows bilayer thickness to increase while maintaining a flat bilayer structure, in contrast to the N-terminal-truncated nanodisc system which adopts an energetically strained lens shape.\",\n      \"method\": \"Small-angle X-ray scattering (SAXS) with molecular constrained data modeling of reconstituted APOA1-POPC-cholesterol discoidal particles; comparison with N-terminal truncated nanodisc system across increasing cholesterol concentrations\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — structural method (SAXS) with modeling; single lab and no mutagenesis validation, but clear structural conclusions\",\n      \"pmids\": [\"26200866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"APOA1 uses a reciprocating thumbwheel-like mechanism to activate LCAT on nascent discoidal HDL: most APOA1 adopts a 5/5 helical registry (helix 5 of one molecule across from helix 5 of the other), but a fraction adopts a 5/2 registry; the 5/2 registry, locked by engineered disulfide bonds, impairs LCAT cholesteryl esterification activity without affecting LCAT binding or macrophage cholesterol efflux, indicating that full LCAT activation requires a hybrid epitope composed of helices 5–7 on one APOA1 molecule and helices 3–4 on the other.\",\n      \"method\": \"Site-directed mutagenesis introducing cysteines at predicted interface positions; disulfide bond locking of specific helical registries; LCAT cholesteryl esterification assay; macrophage cholesterol efflux assay; chemical cross-linking studies\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with functional reconstitution assays and cross-linking structural data; direct mechanistic demonstration of registry-dependent LCAT activation\",\n      \"pmids\": [\"29773713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ApoA1 interacts directly with dengue virus (DENV) non-structural protein 1 (NS1); ApoA1-mediated depletion of lipid rafts from cell membranes inhibits DENV attachment to the cell surface, and ApoA1 neutralizes NS1-induced cell activation and NS1-mediated enhancement of DENV infection, identifying a mechanism by which ApoA1/HDL-mediated reverse cholesterol transport controls viral infection.\",\n      \"method\": \"Co-immunoprecipitation and binding assays between DENV NS1 and ApoA1; lipid raft quantification in cell membranes; DENV infectivity assays with ApoA1 and ApoA1 mimetic peptide 4F; cell activation assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct binding demonstrated with functional infectivity and cell activation assays; single lab but multiple orthogonal readouts\",\n      \"pmids\": [\"33827950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ApoA1 (and ApoJ/Clusterin) modulate amyloid-β1-40 transport across the blood-brain barrier (BBB) by distinct mechanisms: ApoA1 complexed with Aβ1-40 does not enhance Aβ efflux from the brain, but ApoA1 present in the apical (blood) compartment mobilizes Aβ1-40 from the basolateral (brain) side; both ApoA1 and ApoJ cross the BBB via a mechanism involving the LDL receptor-related protein family, but ApoA1 trafficking is restricted when bound to Aβ.\",\n      \"method\": \"In vitro BBB model using primary cerebral endothelial cells on Matrigel-coated Transwells; fluorescently labeled Aβ1-40 transport assays; LRP family inhibitor experiments; measurement of bidirectional transport of recombinant ApoA1 and ApoJ\",\n      \"journal\": \"Journal of Alzheimer's disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reconstituted in vitro BBB model with pharmacological pathway dissection; single lab\",\n      \"pmids\": [\"27232214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ApoA1 binds heparin simultaneously with serum amyloid A (SAA) on HDL isolated from inflamed mice, forming rapid complex aggregates; mass spectrometry of chemically cross-linked HDL-SAA particles detected multiple cross-links between ApoA1 and SAA, indicating these two proteins are in close proximity (within 25 Å) on the HDL surface, providing a structural basis for simultaneous heparin binding.\",\n      \"method\": \"Gel electrophoresis of heparin-HDL complexes; mass spectrometry analysis of chemically cross-linked apoA1-SAA peptides from inflammation-associated HDL\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — chemical cross-linking with MS identifies proximity of ApoA1 and SAA on HDL surface; single lab\",\n      \"pmids\": [\"27105909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ApoA-1 improves glucose tolerance in high-fat diet-fed mice by increasing glucose uptake into skeletal muscle (+110%) and heart (+100%) independently of AMPKα2 kinase activity; the insulin-independent component of this effect requires systemic factors not present in isolated muscle ex vivo, suggesting ApoA-1 acts through an indirect systemic mechanism rather than direct muscle cell signaling via AMPKα2.\",\n      \"method\": \"Recombinant human ApoA-1 injection in wild-type and AMPKα2 kinase-dead mice; glucose tolerance tests with/without insulin secretion block (epinephrine + propranolol); radiolabeled glucose uptake into isolated tissues; isolated skeletal muscle ex vivo glucose uptake assay\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo genetic epistasis (kinase-dead mice) combined with pharmacological block and ex vivo muscle assay; multiple orthogonal readouts ruling out AMPKα2 dependence\",\n      \"pmids\": [\"32244181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HDL and ApoA-1 suppress glucagon expression and secretion from pancreatic α-cells via binding to SCARB-1 (scavenger receptor class B type 1) and activating the PI3K/Akt/FoxO1 signaling cascade; pretreatment with Akt inhibitor VIII, PI3K inhibitor LY294002, or SCARB-1 inhibitor BLT-1 restores α-cell response to low glucose, establishing the receptor and downstream pathway.\",\n      \"method\": \"Treatment of αTC1 clone 6 cells with HDL or ApoA-1; glucagon expression (RT-PCR) and secretion assays; western blotting for Akt and FoxO1 phosphorylation; pharmacological inhibitors of Akt, PI3K, and SCARB-1; in vivo HDL/ApoA-1 injection in CD1 mice measuring glucagon response to insulin-induced hypoglycemia\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro pathway dissection with multiple inhibitors plus in vivo validation; single lab\",\n      \"pmids\": [\"33086869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRIM15 interacts with APOA1 through its PRY/SPRY domain and promotes APOA1 polyubiquitination via its RING domain, leading to APOA1 proteasomal degradation; loss of APOA1 enhances lipid anabolism, promotes lipid droplet accumulation, and drives pancreatic cancer cell invasion and metastasis via the APOA1-LDLR axis regulating triglyceride synthesis.\",\n      \"method\": \"Mass spectrometry identification of TRIM15 binding partners; co-immunoprecipitation of TRIM15 and APOA1; domain-mapping experiments with PRY/SPRY and RING domain mutants; ubiquitination assay; lipid droplet staining; TRIM15 silencing with invasion/migration assays; LDLR pathway analysis\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS-identified interaction confirmed by co-IP with domain mapping and functional ubiquitination assay; single lab\",\n      \"pmids\": [\"34311082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Targeting the Apoa1 locus in mouse liver with CRISPR-Cas9/AAV delivery achieves 6–16% targeted hepatocyte editing; the endogenous Apoa1 promoter drives robust and sustained hepatic expression of therapeutic transgenes (APOE, FAH), validating Apoa1 as a functional integration site for liver-directed gene therapy.\",\n      \"method\": \"AAV delivery of CRISPR-Cas9 targeting mouse Apoa1 locus; quantification of targeted integration rates; plasma lipid measurement in hypercholesterolemia model after APOE knock-in; phenotypic rescue of hereditary tyrosinemia type I by FAH knock-in\",\n      \"journal\": \"Molecular therapy. Methods & clinical development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genome editing with functional rescue phenotype; demonstrates promoter activity for transgene expression; single lab\",\n      \"pmids\": [\"34141821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In small HDL particles, the C-termini of the two antiparallel APOA1 molecules are 'flipped' off the lipid surface, adopting an extended conformation that engages ABCA1 to promote cholesterol efflux; in larger HDL particles, the C-termini form a helical bundle that adheres strongly to the lipid surface, preventing productive ABCA1 interaction. LCAT activity converts small/extra-small HDL into larger particles and markedly inhibits cholesterol efflux capacity, confirming this structural mechanism.\",\n      \"method\": \"Tandem mass spectrometric analysis of chemically cross-linked peptides from reconstituted HDL of four sizes; molecular dynamics simulations of APOA1 conformations; macrophage ABCA1-dependent cholesterol efflux capacity assays; isolation of HDL from LCAT-deficient subjects; incubation with human LCAT to convert particle size distributions\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural (cross-linking MS + MD simulation) combined with functional efflux assay and human genetic model (LCAT deficiency); multiple orthogonal methods supporting same mechanism\",\n      \"pmids\": [\"38018436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In human scleral fibroblasts under hypoxia, FOXM1 represses METTL3 transcription (demonstrated by ChIP showing FOXM1 enrichment at the METTL3 promoter); reduced METTL3 decreases m6A methylation of APOA1 mRNA, reducing YTHDF2-mediated mRNA degradation and thereby stabilizing/increasing APOA1 expression; elevated APOA1 promotes myofibroblast transdifferentiation (elevated vinculin, paxillin, α-SMA) and inhibits collagen production, contributing to scleral remodeling in myopia.\",\n      \"method\": \"ChIP assay for FOXM1 at METTL3 promoter; Me-RIP to measure m6A modification of APOA1 mRNA; PAR-CLIP to examine METTL3-APOA1 mRNA binding; loss/gain-of-function experiments (siRNA knockdown, overexpression); western blotting and RT-qPCR for myofibroblast markers; CCK-8 proliferation and flow cytometry apoptosis assays\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and Me-RIP establish mechanistic pathway; PAR-CLIP confirms binding; multiple functional readouts; single lab\",\n      \"pmids\": [\"38190128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ABCA1-dependent vitamin E (tocopherol) secretion from Caco-2 intestinal cells to APOA1 (but not HDL) is vitamer-selective: T0901317-induced ABCA1 expression drives α- and γ-tocopherol secretion to apical APOA1 more efficiently than δ-tocopherol, while APOB-dependent secretion (accounting for ~80% of total) shows no such selectivity, establishing APOA1 as the acceptor that confers selective tocopherol secretion via the ABCA1 pathway.\",\n      \"method\": \"Caco-2 polarized monolayer system with apical co-incubation of three tocopherols; MTP inhibitor (BMS201038) to quantify apoB-dependent pathway; LXR agonist T0901317 to induce ABCA1; basolateral APOA1 acceptor assays; SR-BI blocking antibody; quantification of tocopherol and cholesterol secretion\",\n      \"journal\": \"The Journal of nutrition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway dissection in polarized cells with multiple inhibitors; directly demonstrates APOA1 as selective acceptor for ABCA1-mediated tocopherol secretion; single lab\",\n      \"pmids\": [\"23946344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"APOA1 binds to triglyceride-rich emulsion particles (model of triglyceride-rich lipoproteins) in a saturable manner with dissociation constant Kd = 7.4 × 10⁻⁷ M; when particle cholesterol content is elevated above the physiological range (>3.7% to 7.3%), the protein binding capacity (N) sharply decreases ~6-fold without changing Kd, suggesting that excess cholesterol content impairs apolipoprotein redistribution and remnant metabolism.\",\n      \"method\": \"Binding of APOA1 and ApoE-3 to isolated triglyceride-phospholipid emulsions of varying cholesterol content; negative stain EM; Scatchard analysis of saturable binding\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro reconstitution binding assay with quantitative kinetics; establishes cholesterol-dependent regulation of APOA1 binding capacity\",\n      \"pmids\": [\"2496752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Following neuronal injury, APOA1 expression increases in a delayed secondary phase response; exogenous ApoA1 treatment accelerates wound closure in a neuroblastoma scratch assay via activation of the ERK signaling pathway and actin polymerization, suggesting ApoA1 plays a functional role in post-injury neuronal healing through these downstream effectors.\",\n      \"method\": \"Proteomics of spinal cord injury tissue at multiple time points; scratch wound healing assay in neuroblastoma cells with ApoA1 treatment; western blotting for ERK pathway activation; actin polymerization assay\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, limited mechanistic depth; ERK activation and actin polymerization shown but pathway not rigorously dissected\",\n      \"pmids\": [\"27734225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ApoA1 mimetic peptide L-4F increases insulin-receptor phosphorylation in mesenchymal stem cell-derived adipocytes via upregulation of heme oxygenase-1 (HO-1); HO activity inhibition reverses L-4F-induced effects on adipogenic markers (increases in WNT10b, decreases in Peg1/Mest), establishing that L-4F acts through an HO-1-dependent mechanism to restore adiponectin secretion, decrease inflammatory cytokines, and improve insulin sensitivity in obese mice.\",\n      \"method\": \"In vivo L-4F administration to ob/ob mice; western blotting for HO-1, insulin receptor phosphorylation, WNT10b, Peg1/Mest; HO activity inhibition pharmacological experiments; adiponectin and cytokine ELISA; cell cycle analysis of MSC-derived adipocytes\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — mimetic peptide (not canonical APOA1 protein), pathway partially mapped; single lab\",\n      \"pmids\": [\"22306989\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOA1, the principal protein of HDL, mediates reverse cholesterol transport by acting as the obligate cofactor of LCAT (activating cholesterol esterification through a thumbwheel-like helical registry mechanism), accepting cholesterol from peripheral cells via ABCA1-dependent efflux (with the C-termini of APOA1 on small HDL particles adopting a flipped conformation that engages ABCA1), and exchanging between lipoprotein classes; its activity is impaired by myeloperoxidase-catalyzed oxidation/nitration at specific residues, regulated post-translationally by TRIM15-mediated ubiquitination and degradation, and modulatable through m6A methylation of its mRNA via the FOXM1/METTL3/YTHDF2 axis; APOA1 additionally activates PI3K/Akt/FoxO1 signaling in pancreatic α-cells through SCARB-1 to suppress glucagon secretion, modulates Aβ transport across the blood-brain barrier via LRP family receptors, and neutralizes dengue virus NS1-mediated lipid raft remodeling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"APOA1 is the principal structural and functional protein of high-density lipoprotein (HDL), organizing lipid particles through an antiparallel double-belt configuration that governs both cholesterol transport and enzyme activation. On discoidal HDL, APOA1 predominantly adopts a 5/5 helical registry but transitions to a 5/2 registry via a thumbwheel mechanism to present a hybrid epitope (helices 5–7 on one chain and helices 3–4 on the other) required for LCAT activation; locking the 5/2 state impairs LCAT cholesteryl esterification without abolishing LCAT binding [PMID:29773713]. In small HDL particles the C-termini of the two APOA1 chains flip off the lipid surface, enabling productive engagement with the ABCA1 transporter and enhanced cholesterol efflux capacity, whereas LCAT-driven particle enlargement sequesters the C-termini in a helical bundle that limits ABCA1 interaction [PMID:38018436]. Beyond reverse cholesterol transport, APOA1 suppresses glucagon secretion from pancreatic α-cells through SCARB1-mediated PI3K/Akt/FoxO1 signaling [PMID:33086869], improves glucose clearance into skeletal and cardiac muscle in vivo [PMID:32244181], and is subject to TRIM15-mediated polyubiquitination and proteasomal degradation that modulates intracellular APOA1 levels and lipid metabolism [PMID:34311082].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Establishing that APOA1 binds lipid particles in a saturable, cholesterol-sensitive manner provided the first quantitative framework for understanding how surface lipid composition controls APOA1 redistribution among lipoproteins.\",\n      \"evidence\": \"In vitro binding to triglyceride–phospholipid emulsions with Scatchard analysis\",\n      \"pmids\": [\"2496752\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Binding measured on synthetic emulsions, not native lipoproteins\",\n        \"Mechanism by which cholesterol reduces binding capacity not resolved\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Determining the three-chain helical-dimer-plus-hairpin architecture of spherical HDL resolved a long-standing debate about APOA1 stoichiometry and global organization on mature HDL particles.\",\n      \"evidence\": \"Small-angle neutron scattering with contrast variation, chemical cross-linking, and mass spectrometry on reconstituted spherical HDL\",\n      \"pmids\": [\"21292766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Atomic-resolution structure of the full spherical HDL complex not obtained\",\n        \"Whether the HdHp model applies across all HDL subfractions is untested\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Using a natural APOA1 L202P loss-of-function variant in humans demonstrated that APOA1/HDL contributes ~19% of in vivo tissue cholesterol efflux, quantifying for the first time the HDL-dependent fraction of reverse cholesterol transport in humans and revealing substantial non-HDL efflux pathways.\",\n      \"evidence\": \"¹³C₂-cholesterol isotope infusion with three-compartment pharmacokinetic modeling in APOA1 mutation carriers versus controls\",\n      \"pmids\": [\"23650622\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Only one mutation studied; generalizability across APOA1 variants unclear\",\n        \"Non-HDL pathways contributing to residual efflux not identified\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showing that the APOA1 N-terminal domain is an integral part of the protein belt rather than a separate globular domain refined the structural model of discoidal HDL and explained how cholesterol incorporation adjusts bilayer thickness.\",\n      \"evidence\": \"SAXS with constrained modeling comparing full-length versus N-terminally truncated APOA1 nanodiscs\",\n      \"pmids\": [\"26200866\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single biophysical method (SAXS); no atomic-resolution validation\",\n        \"Functional consequence for LCAT activation or ABCA1 interaction not tested\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identifying the thumbwheel mechanism — registry switching between 5/5 and 5/2 helical states — explained how APOA1 presents a composite epitope that activates LCAT, mechanistically linking APOA1 conformational dynamics to HDL maturation.\",\n      \"evidence\": \"Engineered cysteine disulfide bonds locking specific registries, with LCAT activity and cholesterol efflux assays\",\n      \"pmids\": [\"29773713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Dynamic interconversion rate between registries on native HDL unknown\",\n        \"Whether registry switching also controls other HDL-associated enzymes (e.g., PON1) untested\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating that APOA1 suppresses glucagon secretion from α-cells via SCARB1→PI3K→Akt→FoxO1 established a non-lipid endocrine signaling function for APOA1, expanding its role beyond cholesterol transport to glucose homeostasis.\",\n      \"evidence\": \"Recombinant APOA1/HDL treatment of αTC1-6 cells with pharmacological inhibitors of Akt, PI3K, and SCARB1, plus in vivo mouse injection\",\n      \"pmids\": [\"33086869\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Genetic ablation of SCARB1 specifically in α-cells not performed\",\n        \"Whether this pathway operates in human islets not confirmed\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showing that recombinant APOA1 improves glucose tolerance and muscle glucose clearance in vivo — but not in isolated muscle ex vivo — indicated that APOA1's metabolic effects require systemic intermediaries and are independent of AMPKα2.\",\n      \"evidence\": \"Recombinant APOA1 injection in high-fat-diet-fed wild-type and AMPKα2 kinase-dead mice with in vivo glucose tolerance and ex vivo muscle uptake assays\",\n      \"pmids\": [\"32244181\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Identity of systemic factor(s) mediating muscle glucose uptake unknown\",\n        \"Receptor mediating APOA1's indirect action on muscle not identified\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying TRIM15 as an E3 ubiquitin ligase that polyubiquitinates APOA1 via its RING domain revealed a proteostatic control mechanism for intracellular APOA1 levels, linking APOA1 degradation to lipid anabolism and cancer cell invasion.\",\n      \"evidence\": \"Mass spectrometry interactome, reciprocal Co-IP, ubiquitination assay, TRIM15 knockdown/overexpression with lipid and invasion readouts in pancreatic cancer cells\",\n      \"pmids\": [\"34311082\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Specific ubiquitin chain type (K48 vs. K63) not determined\",\n        \"Relevance to hepatocyte APOA1 secretion and systemic HDL levels untested\",\n        \"Single lab; not independently confirmed\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealing that small HDL particles expose APOA1 C-termini for ABCA1 engagement while LCAT-driven enlargement buries them provided a structural switch model that unifies HDL size, APOA1 conformation, and cholesterol efflux capacity.\",\n      \"evidence\": \"Cross-linking mass spectrometry, molecular dynamics simulations, CEC assays with LCAT-deficient human plasma, calibrated ion mobility analysis\",\n      \"pmids\": [\"38018436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct cryo-EM or crystallographic visualization of the C-terminal flip not yet achieved\",\n        \"Whether additional HDL-remodeling enzymes (CETP, PLTP) modulate C-terminal exposure is unresolved\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution atomic structure of full-length APOA1 on native HDL particles — capturing both registry states and the C-terminal conformational switch — remains unresolved and is needed to integrate the thumbwheel and C-terminal flip models into a unified dynamic picture of HDL function.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No cryo-EM or crystal structure of full APOA1 on intact HDL\",\n        \"In vivo regulation of registry switching and C-terminal exposure kinetics unknown\",\n        \"Relative contribution of APOA1 signaling (PI3K/Akt, ERK) versus cholesterol transport to whole-body metabolic outcomes not quantified\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 1, 2, 3, 15]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 2, 4, 11, 15]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 1, 4, 13, 15]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5, 7, 8]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"complexes\": [\n      \"HDL (high-density lipoprotein)\"\n    ],\n    \"partners\": [\n      \"LCAT\",\n      \"ABCA1\",\n      \"SCARB1\",\n      \"TRIM15\",\n      \"SAA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"APOA1, the principal structural and functional protein of high-density lipoproteins (HDL), orchestrates reverse cholesterol transport by activating lecithin:cholesterol acyltransferase (LCAT) through a helical-registry-dependent mechanism, accepting cholesterol and other lipids from peripheral cells via ABCA1-dependent efflux, and serving as a reservoir for exchangeable apolipoproteins that transfer between lipoprotein classes [PMID:4335615, PMID:4345202, PMID:29773713]. On small HDL particles, the C-termini of antiparallel APOA1 molecules adopt a flipped conformation that engages ABCA1 to promote cholesterol efflux; LCAT-driven particle maturation converts this active conformation into a lipid-adherent helical bundle that suppresses efflux capacity, and myeloperoxidase-catalyzed oxidation of APOA1 independently impairs ABCA1-dependent efflux, rendering HDL dysfunctional [PMID:38018436, PMID:15314690]. Beyond lipid transport, APOA1 suppresses glucagon secretion from pancreatic α-cells through SCARB1-mediated activation of the PI3K/Akt/FoxO1 cascade, improves glucose tolerance by increasing skeletal muscle glucose uptake independently of AMPKα2, and modulates amyloid-β transport across the blood–brain barrier via LRP family receptors [PMID:33086869, PMID:32244181, PMID:27232214]. Germline loss-of-function variants in APOA1 cause low HDL cholesterol, and position-specific amyloidogenic mutations cause hereditary apolipoprotein A-I amyloidosis (AApoAI) with organ tropism determined by the mutation location [PMID:15297675, PMID:19324996].\",\n  \"teleology\": [\n    {\n      \"year\": 1972,\n      \"claim\": \"Establishing that APOA1 is the obligate protein cofactor for LCAT resolved how plasma cholesterol esterification is catalyzed and positioned APOA1 as the central functional component of HDL-mediated lipid metabolism.\",\n      \"evidence\": \"In vitro reconstitution assay measuring LCAT activity with and without apolipoprotein fractions\",\n      \"pmids\": [\"4335615\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of LCAT activation by APOA1 was unknown\", \"Which APOA1 domains are required for activation was not determined\"]\n    },\n    {\n      \"year\": 1973,\n      \"claim\": \"Demonstrating that HDL/APOA1 particles donate exchangeable apolipoproteins (apoC) to chylomicrons during alimentary lipemia established HDL as a dynamic reservoir that facilitates triglyceride metabolism across lipoprotein classes.\",\n      \"evidence\": \"In vivo human metabolic study with apolipoprotein quantification across lipoprotein fractions before and after fat meals\",\n      \"pmids\": [\"4345202\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of apolipoprotein transfer between particles was not defined\", \"Role of specific APOA1 domains in exchange was unknown\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Quantifying APOA1 binding to triglyceride-rich emulsion particles and showing that excess cholesterol sharply reduces binding capacity revealed a lipid-composition-dependent gating mechanism for apolipoprotein redistribution.\",\n      \"evidence\": \"In vitro binding assay with Scatchard analysis on TG-phospholipid emulsions of varying cholesterol content\",\n      \"pmids\": [\"2496752\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether this binding modulation occurs on native lipoproteins in vivo was not tested\", \"Structural basis of cholesterol-induced reduction in binding sites was not resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identifying myeloperoxidase as a direct binding partner that nitrates/chlorinates APOA1 on HDL and selectively impairs ABCA1-dependent cholesterol efflux established a molecular mechanism for generating dysfunctional HDL in atherosclerotic disease.\",\n      \"evidence\": \"Co-immunoprecipitation, mass spectrometry of oxidative modifications in lesion-derived APOA1, and macrophage cholesterol efflux assays\",\n      \"pmids\": [\"15314690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific modified residues are responsible for efflux impairment was not fully resolved\", \"Whether MPO-modified APOA1 gains toxic gain-of-function activities was not addressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Population-based resequencing with functional validation showed that rare loss-of-function APOA1 variants collectively explain a substantial fraction of low HDL-C in the general population, establishing APOA1 as a direct genetic determinant of plasma HDL levels.\",\n      \"evidence\": \"Resequencing of APOA1 in extreme HDL-C phenotype groups with biochemical functional studies of variants\",\n      \"pmids\": [\"15297675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Effect sizes of individual rare variants on cardiovascular outcomes were not determined\", \"Functional consequences beyond HDL-C levels (e.g., efflux capacity) were not measured for each variant\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Mapping amyloidogenic APOA1 mutations to two hot-spot regions and correlating mutation position with organ-specific amyloid deposition established genotype–phenotype relationships for hereditary AApoAI amyloidosis.\",\n      \"evidence\": \"Germline sequencing and Congo red/immunohistochemistry-confirmed biopsy across multiple patients\",\n      \"pmids\": [\"19324996\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for why different regions produce different amyloid fibrils with different tissue tropism was unknown\", \"Whether amyloid toxicity is from loss of HDL function or gain-of-function aggregation was not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Determining that three APOA1 chains form a helical dimer-with-hairpin architecture on spherical HDL provided the first solution-phase structural model of mature HDL, resolving how a protein shell cradles a lipid core.\",\n      \"evidence\": \"Small-angle neutron scattering with contrast variation combined with chemical cross-linking/mass spectrometry on reconstituted spherical HDL\",\n      \"pmids\": [\"21292766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution structure of full-length APOA1 on HDL was not achieved\", \"Conformational dynamics during particle remodeling were not captured\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Stable isotope kinetic studies in human APOA1 L202P carriers quantified, for the first time, the in vivo contribution of APOA1 to tissue cholesterol efflux (~19% reduction with mutation), while revealing substantial non-HDL reverse cholesterol transport pathways.\",\n      \"evidence\": \"In vivo ¹³C₂-cholesterol infusion with three-compartment kinetic modeling and fecal sterol recovery in mutation carriers versus controls\",\n      \"pmids\": [\"23650622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the non-HDL efflux pathways was not established\", \"Whether the L202P mutation affects efflux capacity per particle or reduces particle number was not distinguished\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"SAXS analysis demonstrated that the N-terminal domain of full-length APOA1 integrates into the protein belt of discoidal HDL particles and accommodates cholesterol-induced bilayer thickening, clarifying its structural role beyond a separate globular domain.\",\n      \"evidence\": \"SAXS with constrained modeling of reconstituted APOA1-POPC-cholesterol discoidal particles compared to N-terminal-truncated nanodiscs\",\n      \"pmids\": [\"26200866\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mutagenesis to validate N-terminal integration was not performed\", \"Dynamic conformational changes during cholesterol loading were not time-resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Multiple non-lipid functions of APOA1 were established: modulation of Aβ1-40 transport across a reconstituted blood–brain barrier via LRP family receptors, direct interaction with dengue NS1 to neutralize lipid raft remodeling and viral infection, and selective acceptance of vitamin E via ABCA1 from intestinal enterocytes.\",\n      \"evidence\": \"In vitro BBB Transwell model with LRP inhibitors; co-IP of APOA1 with dengue NS1 and infectivity assays; polarized Caco-2 monolayer tocopherol secretion with ABCA1 induction and MTP inhibition\",\n      \"pmids\": [\"27232214\", \"33827950\", \"23946344\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of APOA1-Aβ interaction for Alzheimer's disease progression was not tested\", \"Structural basis of NS1-APOA1 interaction was not mapped\", \"Whether selective tocopherol transfer occurs in vivo was not confirmed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Disulfide-locking experiments revealed that APOA1 activates LCAT through a reciprocating thumbwheel mechanism dependent on helical registry: the 5/5 registry is the predominant conformation, but a hybrid epitope spanning helices 5–7 and 3–4 of adjacent APOA1 molecules in the 5/5 registry is required for full catalytic activation.\",\n      \"evidence\": \"Engineered cysteine mutations to lock 5/2 versus 5/5 registries; LCAT cholesteryl ester formation assay and macrophage cholesterol efflux assay\",\n      \"pmids\": [\"29773713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic structure of the APOA1-LCAT complex was not resolved\", \"How registry shifts are regulated in vivo (e.g., by lipid composition) was not determined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"APOA1 was shown to regulate glucose homeostasis through two distinct mechanisms: suppressing glucagon secretion from pancreatic α-cells via SCARB1/PI3K/Akt/FoxO1 signaling, and enhancing skeletal muscle glucose uptake through a systemic, AMPKα2-independent mechanism.\",\n      \"evidence\": \"Pharmacological inhibitor panel (Akt, PI3K, SCARB1 blockers) in αTC1 cells with in vivo validation; recombinant APOA1 injection in wild-type and AMPKα2 kinase-dead mice with radiolabeled glucose uptake\",\n      \"pmids\": [\"33086869\", \"32244181\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The systemic factor mediating muscle glucose uptake downstream of APOA1 was not identified\", \"Whether the glucagon-suppressive effect is physiologically relevant at endogenous APOA1 concentrations was not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery that TRIM15 ubiquitinates APOA1 via its RING domain (recognized through the PRY/SPRY domain) for proteasomal degradation identified the first E3 ligase regulating APOA1 turnover and linked APOA1 loss to lipid droplet accumulation and pancreatic cancer metastasis via the LDLR axis.\",\n      \"evidence\": \"Mass spectrometry-identified interaction confirmed by co-IP, domain-mapping mutagenesis, ubiquitination assays, and invasion/migration assays in pancreatic cancer cells\",\n      \"pmids\": [\"34311082\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether TRIM15-mediated APOA1 degradation occurs in hepatocytes or in circulation was not tested\", \"In vivo significance of TRIM15-APOA1 axis for lipid metabolism was not demonstrated\", \"Ubiquitination sites on APOA1 were not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolving the C-terminal conformational switch between small and large HDL particles explained size-dependent cholesterol efflux: on small HDL the flipped C-termini engage ABCA1, while LCAT-driven maturation locks C-termini onto the lipid surface, inhibiting efflux — unifying the opposing roles of LCAT activation and efflux capacity.\",\n      \"evidence\": \"Cross-linking MS and MD simulation across four HDL sizes; ABCA1-dependent efflux assays; HDL from LCAT-deficient subjects incubated with recombinant LCAT\",\n      \"pmids\": [\"38018436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the C-terminal flip is a therapeutic target for enhancing cholesterol efflux has not been tested\", \"Structural details of the APOA1 C-terminus–ABCA1 interaction interface are not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of the FOXM1/METTL3/YTHDF2 axis regulating APOA1 mRNA stability via m6A methylation revealed an epitranscriptomic layer of APOA1 regulation, linking it to scleral fibroblast transdifferentiation in myopia.\",\n      \"evidence\": \"ChIP for FOXM1 at METTL3 promoter; Me-RIP and PAR-CLIP for m6A modification and METTL3 binding of APOA1 mRNA; knockdown/overexpression in human scleral fibroblasts under hypoxia\",\n      \"pmids\": [\"38190128\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether m6A-mediated regulation of APOA1 occurs in hepatocytes (the major source of circulating APOA1) was not examined\", \"In vivo relevance to myopia progression was not demonstrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic-resolution structure of APOA1 in complex with LCAT and ABCA1, the identity of the systemic mediator of APOA1-induced muscle glucose uptake, and whether therapeutic manipulation of the C-terminal conformational switch or TRIM15-mediated degradation can enhance reverse cholesterol transport in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution APOA1-LCAT or APOA1-ABCA1 co-structure exists\", \"Systemic mediator of APOA1 glucose uptake effect unidentified\", \"Therapeutic relevance of TRIM15-APOA1 axis untested in vivo\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 5, 6, 8, 17, 20]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 9, 17]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [1, 7, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 2, 5, 7, 17, 20]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 7, 9, 17, 19, 20]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [2, 7, 17, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [14]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"complexes\": [\n      \"HDL particle\"\n    ],\n    \"partners\": [\n      \"LCAT\",\n      \"ABCA1\",\n      \"MPO\",\n      \"SCARB1\",\n      \"TRIM15\",\n      \"SAA\",\n      \"LDLR\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}